

(19) World Intellectual Property
Organization
International Bureau



(43) International Publication Date
3 March 2005 (03.03.2005)

PCT

(10) International Publication Number
WO 2005/019171 A1

(51) International Patent Classification⁷: **C07D 209/36**

(21) International Application Number:
PCT/GB2004/003502

(22) International Filing Date: 16 August 2004 (16.08.2004)

(25) Filing Language: English

(26) Publication Language: English

(30) Priority Data:
0302232-4 18 August 2003 (18.08.2003) SE

(71) Applicant (for all designated States except MG, US):
ASTRAZENECA AB [SE/SE]; Sodertalje, S-SE-151 85
(SE).

(71) Applicant (for MG only): ASTRAZENECA UK LIM-
ITED [GB/GB]; 15 Stanhope Gate, London Greater Lon-
don W1K 1LN (GB).

(72) Inventors; and

(75) Inventors/Applicants (for US only): BONNERT, Roger,
Victor [GB/GB]; AstraZeneca R & D Charnwood,
Bakewell Road, Loughborough Leicestershire LE11 5RH
(GB). COOK, Anthony, Ronald [GB/GB]; AstraZeneca
R & D Charnwood, Bakewell Road, Loughborough Le-
icestershire LE11 5RH (GB). LUKER, Timothy, Jon
[GB/GB]; AstraZeneca R D Charnwood, Bakewell Road,
Loughborough Leicestershire LE11 5RH (GB). MO-
HAMMED, Rukhsana, Tasneem [GB/GB]; AstraZeneca

R & D Charnwood, Bakewell Road, Loughborough Le-
icestershire LE11 5RH (GB). THOM, Stephen [GB/GB];
AstraZeneca R & D Charnwood, Bakewell Road, Lough-
borough Leicestershire LE11 5RH (GB).

(74) Agent: ASTRAZENECA; Global Intellectual Property,
S-151 85 Sodertalje (SE).

(81) Designated States (unless otherwise indicated, for every
kind of national protection available): AE, AG, AL, AM,
AT, AU, AZ, BA, BB, BG, BR, BW, BY, BZ, CA, CH, CN,
CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, EG, ES, FI,
GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE,
KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD,
MG, MK, MN, MW, MX, MZ, NA, NI, NO, NZ, OM, PG,
PH, PL, PT, RO, RU, SC, SD, SE, SG, SK, SL, SY, TJ, TM,
TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, YU, ZA, ZM,
ZW.


(84) Designated States (unless otherwise indicated, for every
kind of regional protection available): ARIPO (BW, GH,
GM, KE, LS, MW, MZ, NA, SD, SL, SZ, TZ, UG, ZM,
ZW), Eurasian (AM, AZ, BY, KG, KZ, MD, RU, TJ, TM),
European (AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI,
FR, GB, GR, HU, IE, IT, LU, MC, NL, PL, PT, RO, SE, SI,
SK, TR), OAPI (BF, BJ, CF, CG, CI, CM, GA, GN, GQ,
GW, ML, MR, NE, SN, TD, TG).

Published:

— with international search report

For two-letter codes and other abbreviations, refer to the "Guid-
ance Notes on Codes and Abbreviations" appearing at the begin-
ning of each regular issue of the PCT Gazette.

(54) Title: SUBSTITUTED INDOLE DERIVATIVES FOR PHARMACEUTICAL COMPOSITION FOR TREATING RESPIRA-
TORY DISEASES



(I)

(57) Abstract: The present invention relates to substituted indoles of formula (I) useful as pharmaceutical compounds for treating respiratory disorders.


WO 2005/019171 A1

SUBSTITUTED INDOLE DERIVATIVES FOR PHARMACEUTICAL COMPOSITIONS FOR TREATING RESPIRATORY DISEASES

The present invention relates to substituted indoles useful as pharmaceutical compounds for treating respiratory disorders, pharmaceutical compositions containing them, and processes for their preparation.

EPA 1 170 594 discloses methods for the identification of compounds useful for the treatment of disease states mediated by prostaglandin D2, a ligand for orphan receptor CRTh2. GB 1356834 discloses a series of compounds said to possess anti-inflammatory, analgesic and antipyretic activity. It has now surprisingly been found that certain indole acetic acids are active at the CRTh2 receptor, and as a consequence are expected to be potentially useful for the treatment of various respiratory diseases, including asthma and COPD.

In a first aspect the invention therefore provides a compound of formula (I) or a pharmaceutically acceptable salt or solvate thereof:



(I)

in which

R¹ is one or more substituents selected from hydrogen, halogen, CN, nitro, SO₂R⁴, OH, OR⁴, S(O)ₓR⁴, SO₂NR⁵R⁶, CONR⁵R⁶, NR⁵R⁶, NR⁹SO₂R⁴, NR⁹SO₂NR⁵R⁶, NR⁹CO₂R⁴, NR⁹COR⁴, aryl, heteroaryl, C₂-C₆ alkenyl, C₂-C₆ alkynyl or C₁-₆ alkyl, the latter five groups being optionally substituted by one or more substituents independently selected from halogen, CN, NR⁹SO₂R⁴, NR⁹CO₂R⁴, NR⁹COR⁴, OR⁸ and NR⁵R⁶, S(O)ₓR⁷ where x is 0, 1 or 2;

R^2 is hydrogen, halogen, CN, SO_2R^4 or $CONR^5R^6$, CH_2OH , CH_2OR^4 or C_{1-7} alkyl, the latter group being optionally substituted by one or more substituents independently selected from halogen atoms, OR^8 and NR^5R^6 , $S(O)_xR^7$ where x is 0, 1 or 2;

R^3 is aryl or heteroaryl each of which is optionally substituted by one or more substituents independently selected from hydrogen, halogen, CN, nitro, OH, SO_2R^4 , OR^4 , SR^4 , SOR^4 , $SO_2NR^5R^6$, $CONR^5R^6$, NR^5R^6 , $NHSO_2R^4$, $NHCO_2R^4$, $NHCOR^4$, $NR^7SO_2R^4$, $NR^7CO_2R^4$, NR^7COR^4 , NHC_{1-6} alkyl NR^5R^6 , C_2-C_6 alkenyl, C_2-C_6 alkynyl, C_{1-6} alkyl, the latter three groups being optionally substituted by one or more substituents independently selected from halogen atoms, CN, OR^8 and NR^5R^6 , $S(O)_xR^7$ where $x = 0, 1$ or 2;

R^4 represents aryl, heteroaryl, or C_{1-6} alkyl all of which may be optionally substituted by one or more substituents independently selected from halogen atoms, aryl, heteroaryl, OR^{10} , OH, $NR^{11}R^{12}$, $S(O)_xR^{13}$ (where $x = 0, 1$ or 2), $CONR^{14}R^{15}$, $NR^{14}COR^{15}$, $SO_2NR^{14}R^{15}$, $NR^{14}SO_2R^{15}$, CN, nitro;

R^5 and R^6 independently represent a hydrogen atom, a C_{1-6} alkyl group, or an aryl, or a heteroaryl, the latter three of which may be optionally substituted by one or more substituents independently selected from halogen atoms, aryl, OR^8 and $NR^{14}R^{15}$, $CONR^{14}R^{15}$, $NR^{14}COR^{15}$, $SO_2NR^{14}R^{15}$, $NR^{14}SO_2R^{15}$; CN, nitro

or

R^5 and R^6 together with the nitrogen atom to which they are attached can form a 3-8 membered saturated heterocyclic ring optionally containing one or more atoms selected from O, $S(O)_x$ where $x = 0, 1$ or 2, NR^{16} , and itself optionally substituted by C_{1-3} alkyl;

R^7 and R^{13} independently represent a C_1-C_6 , alkyl, an aryl or a heteroaryl group, all of which may be optionally substituted by halogen atoms;

R^8 represents a hydrogen atom, $C(O)R^9$, C_1-C_6 alkyl (optionally substituted by halogen atoms or aryl) an aryl or a heteroaryl group (optionally substituted by halogen);

each of R^9 , R^{10} , R^{11} , R^{12} , R^{14} , R^{15} , independently represents a hydrogen atom, C_1-C_6 alkyl, an aryl or a heteroaryl group (all of which may be optionally substituted by halogen atoms); and

R^{16} is hydrogen, C_{1-4} alkyl, $-COC_1-C_4$ alkyl, $COYC_1-C_4$ alkyl where Y is O or NR^7 .

In the context of the present specification, unless otherwise indicated, an alkyl or alkenyl group or an alkyl or alkenyl moiety in a substituent group may be linear, branched or cyclic.

Aryl is phenyl or naphthyl.

Heteroaryl as used herein is defined as a 5-7 membered aromatic ring or can be a 6,6- or 6,5-fused bicyclic group, both the mono- and bi-cyclic rings containing one or more heteroatoms selected from N, S and O. Examples include pyridine, pyrimidine, thiazole, oxazole, pyrazole, imidazole, furan, isoxazole, pyrrole, isothiazole and azulene, naphthyl, indene, quinoline, isoquinoline, indole, indolizine, benzo[b]furan, benzo[b]thiophene, 1H-indazole, benzimidazole, benzthiazole, 1,2benzisothiazole, benzoxazole, purine, 4H-quinolizine, cinnoline, phthalazine, quinazoline, quinoxaline, 1,8-naphthyridine, pteridine and quinolone.

Heterocyclic rings as defined for R⁵ and R⁶ means saturated heterocycles, examples include morpholine, thiomorpholine, azetidine, imidazolidine, pyrrolidine, piperidine and piperazine.

The term alkyl, whether alone or as part of another group, includes straight chain, branched or cyclic alkyl groups.

Preferably R¹ is hydrogen, halogen, heteroaryl, CF₃, alkyl, cyano, CONR⁵R⁶, SO₂NR⁵R⁶, SO₂alkyl, NR⁹SO₂R⁴, NR⁹COR⁴, NR⁹SO₂NR⁵R⁶. More preferably R¹ is hydrogen, chlorine, fluorine, NHSO₂Me, NHSO₂Et, SO₂Me, CF₃, NHCOMe, pyrazinyl, or NHSO₂NMe₂.

The R¹ group can be present at any suitable position on the indole ring, preferably the R¹ group is present at the 4 or 5-position.

Preferably R² is C₁₋₆alkyl, more preferably methyl.

Suitably R³ is phenyl or heteroaryl. Suitable heteroaryl groups includes a 6,6- or 6,5-fused bicyclic aromatic ring systems optionally containing one to three heteroatoms selected from nitrogen, oxygen or sulphur, or a 5- to 7-membered heterocyclic ring containing one to three heteroatoms selected from nitrogen, oxygen or sulphur as described above. When R³ is a heterocycle, heteroatom(s) can be present at any position in the ring.

The substituent can be present on any suitable position of the aryl or heteroaryl ring.

Preferably R³ is phenyl substituted by halogen atoms, CONR⁵R⁶, SO₂NR⁵R⁶, cyano or SO₂R⁴ groups. The substituent(s) may be present on any position of the phenyl ring. More preferably the substituents are chlorine or SO₂alkyl, CONHC₁₋₆ alkyl (where the alkyl group maybe linear or branched and optionally substituted by NR⁵R⁶, SO₂NR⁵R⁶) or R³ is cyano. Most preferably the substituents are chlorine or SO₂Me, CONHMe, CONHEt, CONHPr,

NH(CH₂)₃NH₂ or cyano. Preferably the substituent is present at the 4-position of the phenyl ring.

Preferred compounds of the invention include:


- 3-(4-Chlorophenoxy)-5-fluoro-2-methyl-1*H*-indole-1-acetic acid;
5-Fluoro-2-methyl-3-[4-(methylsulfonyl)phenoxy]-1*H*-indole-1-acetic acid;
3-(4-Chlorophenoxy)-2-methyl-4-[(methylsulfonyl)amino]-1*H*-indole-1-acetic acid;
4-(Acetylamino)-3-(4-chlorophenoxy)-2-methyl-1*H*-indole-1-acetic acid;
5 3-(4-chlorophenoxy)-2-methyl-5-(methylsulfonyl)-1*H*-indole-1-acetic acid;
3-(4-chlorophenoxy)-2-methyl-5-(trifluoromethyl)-1*H*-indole-1-acetic acid;
3-(4-Chlorophenoxy)-2-methyl-5-[(methylsulfonyl)amino]-1*H*-indole-1-acetic acid;
3-(4-Chlorophenoxy)-5-[(ethylsulfonyl)amino]-2-methyl-1*H*-indole-1-acetic acid;
3-(4-Carboxyphenoxy)-5-fluoro-2-methyl-1*H*-indole-1-acetic acid;
10 5-Fluoro-2-methyl-3-[4-[(methylamino)carbonyl]phenoxy]-1*H*-indole-1-acetic acid;
3-[4-[(Ethylamino)carbonyl]phenoxy]-5-fluoro-2-methyl-1*H*-indole-1-acetic acid;
5-Fluoro-2-methyl-3-[4-[(1-methylethyl)amino]carbonyl]phenoxy]-1*H*-indole-1-acetic acid;
3-(4-Carboxyphenoxy)-5-chloro-2-methyl-1*H*-indole-1-acetic acid;
5-Fluoro-3-[4-(methoxycarbonyl)phenoxy]-2-methyl-1*H*-indole-1-acetic acid;
15 5-Chloro-3-[4-(methoxycarbonyl)phenoxy]-2-methyl-1*H*-indole-1-acetic acid;
5-Chloro-2-methyl-3-[4-[(methylamino)carbonyl]phenoxy]-1*H*-indole-1-acetic acid;
5-Chloro-3-[4-[(ethylamino)carbonyl]phenoxy]-2-methyl-1*H*-indole-1-acetic acid;
Sodium 5-Chloro-2-methyl-3-[4-[(1-methylethyl)amino]carbonyl]phenoxy]-1*H*-indole-1-
acetate;
20 3-[4-[(2-Aminoethyl)amino]carbonyl]phenoxy]-5-fluoro-2-methyl-1*H*-indole-1-acetic acid;
2,5-Dimethyl-3-[4-(methylsulfonyl)phenoxy]-1*H*-indole-1-acetic acid;
2-Methyl-3-[4-(methylsulfonyl)phenoxy]-5-(trifluoromethyl)-1*H*-indole-1-acetic acid;
5-Chloro- α ,2-dimethyl-3-[4-(methylsulfonyl)phenoxy]-1*H*-indole-1-acetic acid;
5-Cyano-2-methyl-3-[4-(methylsulfonyl)phenoxy]-1*H*-indole-1-acetic acid;
25 3-(4-Chlorophenoxy)-4-[(ethylsulfonyl)amino]-2-methyl-1*H*-indole-1-acetic acid;
3-(4-Chlorophenoxy)-4-[(dimethylamino)sulfonyl]amino]-2-methyl-1*H*-indole-1-acetic acid;
3-(4-Chlorophenoxy)-2-methyl-4-pyrazinyl-1*H*-indole-1-acetic acid;
3-(4-Chlorophenoxy)-2-methyl-4-[(1-methylethyl)sulfonyl]amino]-1*H*-indole-1-acetic acid;
3-[4-[(Dimethylamino)sulfonyl]phenoxy]-5-fluoro-2-methyl-1*H*-indole-1-acetic acid;
30 3-[4-(Ethylsulfonyl)phenoxy]-5-fluoro-2-methyl-1*H*-indole-1-acetic acid;
3-[4-(Ethylsulfonyl)phenoxy]-2-methyl-5-(trifluoromethyl)-1*H*-indole-1-acetic acid;

3-(4Cyanophenoxy)-2-methyl-5-(trifluoromethyl)-1*H*-indole-1-acetic acid;
 3-(4-Cyanophenoxy)-5-fluoro-2-methyl-1*H*-indole-1-acetic acid;
 and pharmaceutically acceptable salts thereof.

Certain compounds of formula (I) are capable of existing in stereo isomeric forms. It will be
 5 understood that the invention encompasses all geometric and optical isomers of the compounds
 of formula (I) and mixtures thereof including racemates. Tautomers and mixtures thereof also
 form an aspect of the present invention.

The compound of formula (I) above may be converted to a pharmaceutically acceptable salt
 or solvate thereof, preferably a basic addition salt such as ammonium, sodium, potassium,
 10 calcium, aluminium, lithium, magnesium, zinc, benzathine, chlorprocaine, choline,
 diethanolamine, ethanolamine, ethyldiamine, meglumine, tromethamine or procaine, or an acid
 addition salt such as a hydrochloride, hydrobromide, phosphate, acetate, fumarate, maleate,
 tartrate, citrate, oxalate, methanesulphonate or *p*-toluenesulphonate. Preferred salts include
 sodium and ammonium salts.

15 In a second aspect the invention provides a compound of formula (IA) or a pharmaceutically
 acceptable salt or solvate thereof, the compounds of formula (IA) being a sub-set of compounds
 of formula (I) above:



(I)

20 in which

R¹ is one or more substituents selected from hydrogen, halogen, CN, nitro, SO₂R⁴, OH, OR⁴,
 25 S(O)xR⁴, SO₂NR⁵R⁶, CONR⁵R⁶, NR⁵R⁶, NR⁹SO₂R⁴, NR⁹CO₂R⁴, NR⁹COR⁴, aryl, heteroaryl, C₂-
 C₆ alkenyl, C₂-C₆ alkynyl or C₁-₆ alkyl, the latter five groups being optionally substituted by one

or more substituents independently selected from halogen, CN, $\text{NR}^9\text{SO}_2\text{R}^4$, $\text{NR}^9\text{CO}_2\text{R}^4$, NR^9COR^4 , OR^8 and NR^5R^6 , $\text{S(O)}_x\text{R}^7$ where x is 0, 1 or 2;

R^2 is hydrogen, halogen, CN, SO_2R^4 or CONR^5R^6 , CH_2OH , CH_2OR^4 or C_{1-7} alkyl, the latter group being optionally substituted by one or more substituents independently selected from
5 halogen atoms, OR^8 and NR^5R^6 , $\text{S(O)}_x\text{R}^7$ where x is 0, 1 or 2;

R^3 is aryl or heteroaryl each of which is optionally substituted by one or more substituents independently selected from hydrogen, halogen, CN, nitro, OH, SO_2R^4 , OR^4 , SR^4 , SOR^4 , $\text{SO}_2\text{NR}^5\text{R}^6$, CONR^5R^6 , NR^5R^6 , $\text{NH}\text{SO}_2\text{R}^4$, $\text{NH}\text{CO}_2\text{R}^4$, NHCOR^4 , $\text{NR}^7\text{SO}_2\text{R}^4$, $\text{NR}^7\text{CO}_2\text{R}^4$, NR^7COR^4 , $\text{C}_2\text{-C}_6$ alkenyl, $\text{C}_2\text{-C}_6$ alkynyl, C_{1-6} alkyl, the latter three groups being optionally
10 substituted by one or more substituents independently selected from halogen atoms, CN, OR^8 and NR^5R^6 , $\text{S(O)}_x\text{R}^7$ where x = 0, 1 or 2;

R^4 represents aryl, heteroaryl, or C_{1-6} alkyl all of which may be optionally substituted by one or more substituents independently selected from halogen atoms, aryl, heteroaryl, OR^{10} , OH, $\text{NR}^{11}\text{R}^{12}$, $\text{S(O)}_x\text{R}^{13}$ (where x = 0, 1 or 2), $\text{CONR}^{14}\text{R}^{15}$, $\text{NR}^{14}\text{COR}^{15}$, $\text{SO}_2\text{NR}^{14}\text{R}^{15}$, $\text{NR}^{14}\text{SO}_2\text{R}^{15}$,
15 CN, nitro;

R^5 and R^6 independently represent a hydrogen atom, a C_{1-6} alkyl group, or an aryl, or a heteroaryl, the latter three of which may be optionally substituted by one or more substituents independently selected from halogen atoms, aryl, OR^8 and $\text{NR}^{14}\text{R}^{15}$, $\text{CONR}^{14}\text{R}^{15}$, $\text{NR}^{14}\text{COR}^{15}$, $\text{SO}_2\text{NR}^{14}\text{R}^{15}$, $\text{NR}^{14}\text{SO}_2\text{R}^{15}$; CN, nitro

20 or

R^5 and R^6 together with the nitrogen atom to which they are attached can form a 3-8 membered saturated heterocyclic ring optionally containing one or more atoms selected from O, S(O)_x where x = 0, 1 or 2, NR^{16} , and itself optionally substituted by C_{1-3} alkyl;


R^7 and R^{13} independently represent a $\text{C}_1\text{-C}_6$, alkyl, an aryl or a heteroaryl group, all of which
25 may be optionally substituted by halogen atoms;

R^8 represents a hydrogen atom, C(O)R^9 , $\text{C}_1\text{-C}_6$ alkyl (optionally substituted by halogen atoms or aryl) an aryl or a heteroaryl group (optionally substituted by halogen);

each of R^9 , R^{10} , R^{11} , R^{12} , R^{14} , R^{15} , independently represents a hydrogen atom, $\text{C}_1\text{-C}_6$ alkyl, an aryl or a heteroaryl group (all of which may be optionally substituted by halogen atoms); and

30 R^{16} is hydrogen, C_{1-4} alkyl, -COC_{1-4} alkyl, COYC_{1-4} alkyl where Y is O or NR^7 .

In a further aspect the invention provides a process for the preparation of a compound of formula (I) which comprises reaction of a compound of formula (II):



5 (II)

in which R¹, R² and R³ are as defined in formula (I) or are protected derivatives thereof, with a compound of formula (IIA):

10 L-CH₂CO₂R¹⁷ (IIA)

where R¹⁷ is an ester forming group and L is a leaving group in the presence of a base, and optionally thereafter in any order:


- removing any protecting group
- 15 • hydrolysing the ester group R¹⁷ to the corresponding acid
- forming a pharmaceutically acceptable salt or solvate.

The reaction can be carried out in suitable solvents such as THF or DMF using a base such as sodium hydride, potassium carbonate or the like. Suitable groups R¹⁷ include C₁₋₆ alkyl groups such as methyl, ethyl or *tertiary*-butyl. Suitable L is a leaving group such as halo, in particular bromo. Preferably the compound of formula (IIA) is ethyl, methyl or *tertiary*-butyl bromoacetate.

Hydrolysis of the ester group R¹⁷ can be carried out using routine procedures, for example by stirring with aqueous sodium hydroxide or trifluoroacetic acid.

It will be appreciated that certain functional groups may need to be protected using standard protecting groups. The protection and deprotection of functional groups is for example, described in 'Protective Groups in Organic Chemistry', edited by J. W. F. McOmie, Plenum Press (1973), and 'Protective Groups in Organic Synthesis', 3rd edition, T. W. Greene & P. G. M. Wuts, Wiley-Interscience (1999).

Compounds of formula (II) can be prepared by reacting a compound of formula (III) with a compound of formula (IV):




in which R¹, R² and R³ are as defined in formula (I).


Preferably the reaction is carried out in a suitable solvent such as ethanol and then dichloromethane or THF with PCl₃ with heating or at room temperature.

10 Or, the reaction can be carried out in acetic acid.

Compounds of formulae (III), (IV) and (V) are commercially available or can be prepared using standard chemistry well known in the art.



Compounds of formula (II) in which R¹ is NR⁹SO₂R⁴ or NR⁹COR⁴, can be prepared from compounds of formula (VI) in which W is an amino group. The group W is reacted with a suitable acetyl or sulfonyl chloride in the presence of a base such as triethylamine.



Compounds of formula (VI) are prepared from compounds of formula (VII) in which Z is a nitro group. The compounds of formula (VII) are treated with hydrogen in a suitable solvent such as methanol, in the presence of an appropriate catalyst such as platinum on charcoal.

Compounds of formula (VII) are prepared from compounds of formula (III) and (IV) as outlined above.

Certain compounds of formula (II), (VI), (VII) and (IV) are believed to be novel and form a further aspect of the invention.

In a further aspect, the present invention provides the use of a compound of formula (I), a prodrug, pharmaceutically acceptable salt or solvate thereof for use in therapy.

The compounds of formula (I) have activity as pharmaceuticals, in particular as modulators of CRTh2 receptor activity, and may be used in the treatment (therapeutic or prophylactic) of conditions/diseases in human and non-human animals which are exacerbated or caused by excessive or unregulated production of PGD₂ and its metabolites. Examples of such conditions/diseases include:

A compound of the invention, or a pharmaceutically acceptable salt thereof, can be used in the treatment of:

- (1) (respiratory tract) - obstructive diseases of the airways including: asthma, including bronchial, allergic, intrinsic, extrinsic, exercise-induced, drug-induced (including aspirin and NSAID-induced) and dust-induced asthma, both intermittent and persistent and of all severities, and other causes of airway hyper-responsiveness; chronic obstructive pulmonary disease (COPD); bronchitis, including infectious and eosinophilic bronchitis; emphysema; bronchiectasis; cystic fibrosis; sarcoidosis; farmer's lung and related diseases; hypersensitivity pneumonitis; lung fibrosis, including cryptogenic fibrosing alveolitis, idiopathic interstitial pneumonias, fibrosis complicating anti-neoplastic therapy and chronic infection, including tuberculosis and aspergillosis and other fungal infections; complications of lung transplantation; vasculitic and thrombotic disorders of the lung vasculature, and pulmonary hypertension; antitussive activity including treatment of chronic cough associated with inflammatory and secretory conditions of the airways, and iatrogenic cough; acute and chronic rhinitis including rhinitis medicamentosa, and vasomotor rhinitis; perennial and seasonal allergic rhinitis including rhinitis nervosa (hay fever); nasal polyposis; acute viral infection including the common

cold, and infection due to respiratory syncytial virus, influenza, coronavirus (including SARS) and adenovirus.

(2) (bone and joints) arthritides associated with or including osteoarthritis/osteoarthrosis, both primary and secondary to e.g. congenital hip dysplasia; cervical and lumbar spondylitis, and low back and neck pain; rheumatoid arthritis and Still's disease; seronegative spondyloarthropathies including ankylosing spondylitis, psoriatic arthritis, reactive arthritis and undifferentiated spondarthropathy; septic arthritis and other infection-related arthropathies and bone disorders such as tuberculosis, including Potts' disease and Poncet's syndrome; acute and chronic crystal-induced synovitis including urate gout, calcium pyrophosphate deposition disease, and calcium apatite related tendon, bursal and synovial inflammation; Behcet's disease; primary and secondary Sjogren's syndrome; systemic sclerosis and limited scleroderma; systemic lupus erythematosus, mixed connective tissue disease, and undifferentiated connective tissue disease; inflammatory myopathies including dermatomyositis and polymyositis; polymyalgia rheumatica; juvenile arthritis including idiopathic inflammatory arthritides of whatever joint distribution and associated syndromes, and rheumatic fever and its systemic complications; vasculitides including giant cell arteritis, Takayasu's arteritis, Churg-Strauss syndrome, polyarteritis nodosa, microscopic polyarteritis, and vasculitides associated with viral infection, hypersensitivity reactions, cryoglobulins, and paraproteins; low back pain; Familial Mediterranean fever, Muckle-Wells syndrome, and Familial Hibernian Fever, Kikuchi disease; drug-induced arthralgias, tendonitides, and myopathies.

(3) (skin) psoriasis, atopic dermatitis, contact dermatitis or other eczematous dermatoses, and delayed-type hypersensitivity reactions; phyto- and photodermatitis; seborrhoeic dermatitis, dermatitis herpetiformis, lichen planus, lichen sclerosus et atrophica, pyoderma gangrenosum, skin sarcoid, discoid lupus erythematosus, pemphigus, pemphigoid, epidermolysis bullosa, urticaria, angioedema, vasculitides, toxic erythemas, cutaneous eosinophilias, alopecia areata, male-pattern baldness, Sweet's syndrome, Weber-Christian syndrome, erythema multiforme; cellulitis, both infective and non-

infective; panniculitis; cutaneous lymphomas, non-melanoma skin cancer and other dysplastic lesions; drug-induced disorders including fixed drug eruptions.

5 (4) (eyes) blepharitis; conjunctivitis, including perennial and vernal allergic conjunctivitis; iritis; anterior and posterior uveitis; choroiditis; autoimmune; degenerative or inflammatory disorders affecting the retina; ophthalmitis including sympathetic ophthalmitis; sarcoidosis; infections including viral, fungal, and bacterial.

10 (5) (gastrointestinal tract) glossitis, gingivitis, periodontitis; oesophagitis, including reflux; eosinophilic gastro-enteritis, mastocytosis, Crohn's disease, colitis including ulcerative colitis, proctitis, pruritis ani; coeliac disease, irritable bowel syndrome, and food-related allergies which may have effects remote from the gut (for example migraine, rhinitis or eczema).

15 (6) (abdominal) hepatitis, including autoimmune, alcoholic and viral; fibrosis and cirrhosis of the liver; cholecystitis; pancreatitis, both acute and chronic.

20 (7) (genitourinary) nephritis including interstitial and glomerulonephritis; nephrotic syndrome; cystitis including acute and chronic (interstitial) cystitis and Hunner's ulcer; acute and chronic urethritis, prostatitis, epididymitis, oophoritis and salpingitis; vulvo-vaginitis; Peyronie's disease; erectile dysfunction (both male and female).

25 (8) (Allograft rejection) acute and chronic following, for example, transplantation of kidney, heart, liver, lung, bone marrow, skin or cornea or following blood transfusion; or chronic graft versus host disease;

30 (9) (CNS) Alzheimer's disease and other dementing disorders including CJD and nvCJD; amyloidosis; multiple sclerosis and other demyelinating syndromes; cerebral atherosclerosis and vasculitis; temporal arteritis; myasthenia gravis; acute and chronic pain (acute, intermittent or persistent, whether of central or peripheral origin) including visceral pain, headache, migraine, trigeminal neuralgia, atypical facial pain, joint and

bone pain, pain arising from cancer and tumor invasion, neuropathic pain syndromes including diabetic, post-herpetic, and HIV-associated neuropathies; neurosarcoidosis; central and peripheral nervous system complications of malignant, infectious or autoimmune processes.

(10) Other auto-immune and allergic disorders including Hashimoto's thyroiditis, Graves' disease, Addison's disease, diabetes mellitus, idiopathic thrombocytopaenic purpura, eosinophilic fasciitis, hyper-IgE syndrome, antiphospholipid syndrome.

(11) Other disorders with an inflammatory or immunological component; including acquired immune deficiency syndrome (AIDS), leprosy, Sezary syndrome, and paraneoplastic syndromes.

(12) (Cardiovascular); atherosclerosis, affecting the coronary and peripheral circulation; pericarditis; myocarditis, inflammatory and auto-immune cardiomyopathies including myocardial sarcoid; ischaemic reperfusion injuries; endocarditis, valvulitis, and aortitis including infective (e.g. syphilitic); vasculitides; disorders of the proximal and peripheral veins including phlebitis and thrombosis, including deep vein thrombosis and complications of varicose veins.

(13) (Oncology) treatment of common cancers including prostate, breast, lung, ovarian, pancreatic, bowel and colon, stomach, skin and brain tumors and malignancies affecting the bone marrow (including the leukaemias) and lymphoproliferative systems, such as Hodgkin's and non-Hodgkin's lymphoma; including the prevention and treatment of metastatic disease and tumour recurrences, and paraneoplastic syndromes.

(14) Diseases associated with raised levels of PGD_2 or its metabolites.

Thus, the present invention provides a compound of formula (I), or a pharmaceutically-acceptable salt or solvate thereof, as hereinbefore defined for use in therapy.

Preferably the compounds of the invention are used to treat diseases in which the chemokine receptor belongs to the CRTh2 receptor subfamily.

Particular conditions which can be treated with the compounds of the invention are asthma, rhinitis and other diseases in which raised levels of PGD₂ or its metabolites. It is preferred that the compounds of the invention are used to treat asthma.

In a further aspect, the present invention provides the use of a compound of formula (I), or a pharmaceutically acceptable salt or solvate thereof, as hereinbefore defined in the manufacture of a medicament for use in therapy.

The invention further relates to combination therapies wherein a compound of formula (1) or a pharmaceutically acceptable salts, solvate or *in vivo* hydrolysable ester thereof, or a pharmaceutical composition or formulation comprising a compound of formula (1) is administered concurrently or sequentially with therapy and/or an agent for the treatment of any one of asthma, allergic rhinitis, cancer, COPD, rheumatoid arthritis, psoriasis, inflammatory bowel diseases, osteoarthritis or osteoporosis.

In particular, for the treatment of the inflammatory diseases rheumatoid arthritis, psoriasis, inflammatory bowel disease, COPD, asthma and allergic rhinitis the compounds of the invention may be combined with agents such as TNF- α inhibitors such as anti-TNF monoclonal antibodies (such as Remicade, CDP-870 and D.sub2.E.sub7.) and TNF receptor immunoglobulin molecules (such as Enbrel.reg.), non-selective COX-1 / COX-2 inhibitors (such as piroxicam, diclofenac, propionic acids such as naproxen, flubiprofen, fenoprofen, ketoprofen and ibuprofen, fenamates such as mefenamic acid, indomethacin, sulindac, apazone, pyrazolones such as phenylbutazone, salicylates such as aspirin), COX-2 inhibitors (such as meloxicam, celecoxib, rofecoxib, valdecoxib and etoricoxib) low dose methotrexate, lefunomide; ciclesonide; hydroxychloroquine, d-penicillamine, auranofin or parenteral or oral gold.

The present invention still further relates to the combination of a compound of the invention together with a leukotriene biosynthesis inhibitor, 5-lipoxygenase (5-LO) inhibitor or 5-lipoxygenase activating protein (FLAP) antagonist such as zileuton; ABT-761; fenleuton; tepoxalin; Abbott-79175; Abbott-85761; N-(5-substituted)-thiophene-2-alkylsulfonamides; 2,6-di-tert-butylphenol hydrazones; methoxytetrahydropyrans such as Zeneca ZD-2138; the compound SB-210661; pyridinyl-substituted 2-cyanonaphthalene compounds such as L-739,010;

2-cyanoquinoline compounds such as L-746,530; indole and quinoline compounds such as MK-591, MK-886, and BAY x 1005.

The present invention still further relates to the combination of a compound of the invention together with a receptor antagonist for leukotrienes LTB.sub4., LTC.sub4., LTD.sub4., and
5 LTE.sub4. selected from the group consisting of the phenothiazin-3-ones such as L-651,392; amidino compounds such as CGS-25019c; benzoxalamines such as ontazolast; benzenecarboximidamides such as BIIL 284/260; and compounds such as zafirlukast, ablukast, montelukast, pranlukast, verlukast (MK-679), RG-12525, Ro-245913, iralukast (CGP 45715A), and BAY x 7195.

10 The present invention still further relates to the combination of a compound of the invention together with a PDE4 inhibitor including inhibitors of the isoform PDE4D.

The present invention still further relates to the combination of a compound of the invention together with a antihistaminic H.sub1. receptor antagonists such as cetirizine, loratadine, desloratadine, fexofenadine, astemizole, azelastine, and chlorpheniramine.

15 The present invention still further relates to the combination of a compound of the invention together with a gastroprotective H.sub2. receptor antagonist.

The present invention still further relates to the combination of a compound of the invention together with an α .sub1.- and α .sub2.-adrenoceptor agonist vasoconstrictor sympathomimetic agent, such as propylhexedrine, phenylephrine, phenylpropanolamine, pseudoephedrine,
20 naphazoline hydrochloride, oxymetazoline hydrochloride, tetrahydrozoline hydrochloride, xylometazoline hydrochloride, and ethylnorepinephrine hydrochloride.

The present invention still further relates to the combination of a compound of the invention together with anticholinergic agents such as ipratropium bromide; tiotropium bromide; oxitropium bromide; pirenzepine; and telenzepine.

25 The present invention still further relates to the combination of a compound of the invention together with a β .sub1.- to β .sub4.-adrenoceptor agonists such as metaproterenol, isoproterenol, isoprenaline, albuterol, salbutamol, formoterol, salmeterol, terbutaline, orciprenaline, bitolterol mesylate, and pirbuterol; or methylxanthanines including theophylline and aminophylline; sodium cromoglycate; or muscarinic receptor (M1, M2, and M3) antagonist.

30 The present invention still further relates to the combination of a compound of the invention together with an insulin-like growth factor type I (IGF-1) mimetic.

The present invention still further relates to the combination of a compound of the invention together with an inhaled glucocorticoid with reduced systemic side effects, such as prednisone, prednisolone, flunisolide, triamcinolone acetonide, beclomethasone dipropionate, budesonide, fluticasone propionate, and mometasone furoate.

5 The present invention still further relates to the combination of a compound of the invention together with an inhibitor of matrix metalloproteases (MMPs), i.e., the stromelysins, the collagenases, and the gelatinases, as well as aggrecanase; especially collagenase-1 (MMP-1), collagenase-2 (MMP-8), collagenase-3 (MMP-13), stromelysin-1 (MMP-3), stromelysin-2 (MMP-10), and stromelysin-3 (MMP-11) and MMP-12.

10 The present invention still further relates to the combination of a compound of the invention together with other modulators of chemokine receptor function such as CCR1, CCR2, CCR2A, CCR2B, CCR3, CCR4, CCR5, CCR6, CCR7, CCR8, CCR9, CCR10 and CCR11 (for the C-C family); CXCR1, CXCR2, CXCR3, CXCR4 and CXCR5 (for the C-X-C family) and CX₃CR1 for the C-X₃-C family.

15 The present invention still further relates to the combination of a compound of the invention together with antiviral agents such as Viracept, AZT, aciclovir and famciclovir, and antiseptics compounds such as Valant.

20 The present invention still further relates to the combination of a compound of the invention together with cardiovascular agents such as calcium channel blockers, lipid lowering agents such as statins, fibrates, beta-blockers, ACE inhibitors, Angiotensin-2 receptor antagonists and platelet aggregation inhibitors.

25 The present invention still further relates to the combination of a compound of the invention together with CNS agents such as antidepressants (such as sertraline), anti-Parkinsonian drugs (such as deprenyl, L-dopa, Requip, Mirapex, MAOB inhibitors such as selegine and rasagiline, comP inhibitors such as Tasmar, A-2 inhibitors, dopamine reuptake inhibitors, NMDA antagonists, Nicotine agonists, Dopamine agonists and inhibitors of neuronal nitric oxide synthase), and anti-Alzheimer's drugs such as donepezil, tacrine, COX-2 inhibitors, propentofylline or metryfonate.

30 The present invention still further relates to the combination of a compound of the invention together with (i) tryptase inhibitors; (ii) platelet activating factor (PAF) antagonists; (iii) interleukin converting enzyme (ICE) inhibitors; (iv) IMPDH inhibitors; (v) adhesion molecule

inhibitors including VLA-4 antagonists; (vi) cathepsins; (vii) MAP kinase inhibitors; (viii) glucose-6 phosphate dehydrogenase inhibitors; (ix) kinin-B.sub1. - and B.sub2. -receptor antagonists; (x) anti-gout agents, e.g., colchicine; (xi) xanthine oxidase inhibitors, e.g., allopurinol; (xii) uricosuric agents, e.g., probenecid, sulfinpyrazone, and benzbromarone; (xiii) growth hormone secretagogues; (xiv) transforming growth factor (TGF β); (xv) platelet-derived growth factor (PDGF); (xvi) fibroblast growth factor, e.g., basic fibroblast growth factor (bFGF); (xvii) granulocyte macrophage colony stimulating factor (GM-CSF); (xviii) capsaicin cream; (xix) Tachykinin NK.sub1. and NK.sub3. receptor antagonists selected from the group consisting of NKP-608C; SB-233412 (talnetant); and D-4418; (xx) elastase inhibitors selected from the group consisting of UT-77 and ZD-0892; (xxi) TNF α converting enzyme inhibitors (TACE); (xxii) induced nitric oxide synthase inhibitors (iNOS) or (xxiii) chemoattractant receptor-homologous molecule expressed on TH2 cells, (CRTH2 antagonists).

The compounds of the present invention may also be used in combination with osteoporosis agents such as roloxifene, droloxifene, lasofoxifene or fosomax and immunosuppressant agents such as FK-506, rapamycin, cyclosporine, azathioprine, and methotrexate;.

The compounds of the invention may also be used in combination with existing therapeutic agents for the treatment of osteoarthritis. Suitable agents to be used in combination include standard non-steroidal anti-inflammatory agents (hereinafter NSAID's) such as piroxicam, diclofenac, propionic acids such as naproxen, flubiprofen, fenoprofen, ketoprofen and ibuprofen, fenamates such as mefenamic acid, indomethacin, sulindac, apazone, pyrazolones such as phenylbutazone, salicylates such as aspirin, COX-2 inhibitors such as celecoxib, valdecoxib, rofecoxib and etoricoxib, analgesics and intraarticular therapies such as corticosteroids and hyaluronic acids such as hyalgan and synvisc and P2X7 receptor antagonists.

The compounds of the invention can also be used in combination with existing therapeutic agents for the treatment of cancer. Suitable agents to be used in combination include:

(i) antiproliferative/antineoplastic drugs and combinations thereof, as used in medical oncology, such as alkylating agents (for example cis-platin, carboplatin, cyclophosphamide, nitrogen mustard, melphalan, chlorambucil, busulphan and nitrosoureas); antimetabolites (for example antifolates such as fluoropyrimidines like 5-fluorouracil and tegafur, raltitrexed, methotrexate, cytosine arabinoside, hydroxyurea, gemcitabine and paclitaxel (Taxol®);

antitumour antibiotics (for example anthracyclines like adriamycin, bleomycin, doxorubicin, daunomycin, epirubicin, idarubicin, mitomycin-C, dactinomycin and mithramycin); antimetabolic agents (for example vinca alkaloids like vincristine, vinblastine, vindesine and vinorelbine and taxoids like taxol and taxotere); and topoisomerase inhibitors (for example epipodophyllotoxins like etoposide and teniposide, amsacrine, topotecan and camptothecin);

(ii) cytostatic agents such as antioestrogens (for example tamoxifen, toremifene, raloxifene, droloxifene and idoxifene), oestrogen receptor down regulators (for example fulvestrant), antiandrogens (for example bicalutamide, flutamide, nilutamide and cyproterone acetate), LHRH antagonists or LHRH agonists (for example goserelin, leuprorelin and buserelin), progestogens (for example megestrol acetate), aromatase inhibitors (for example anastrozole, letrozole, vorazole and exemestane) and inhibitors of 5 α -reductase such as finasteride;

(iii) Agents which inhibit cancer cell invasion (for example metalloproteinase inhibitors like marimastat and inhibitors of urokinase plasminogen activator receptor function);

(iv) inhibitors of growth factor function, for example such inhibitors include growth factor antibodies, growth factor receptor antibodies (for example the anti-erbB2 antibody trastuzumab [HerceptinTM] and the anti-erbB1 antibody cetuximab [C225]), farnesyl transferase inhibitors, tyrosine kinase inhibitors and serine/threonine kinase inhibitors, for example inhibitors of the epidermal growth factor family (for example EGFR family tyrosine kinase inhibitors such as N-(3-chloro-4-fluorophenyl)-7-methoxy-6-(3-morpholinopropoxy)quinazolin-4-amine (gefitinib, AZD1839), N-(3-ethynylphenyl)-6,7-bis(2-methoxyethoxy)quinazolin-4-amine (erlotinib, OSI-774) and 6-acrylamido-N-(3-chloro-4-fluorophenyl)-7-(3-morpholinopropoxy)quinazolin-4-amine (CI 1033)), for example inhibitors of the platelet-derived growth factor family and for example inhibitors of the hepatocyte growth factor family;

(v) antiangiogenic agents such as those which inhibit the effects of vascular endothelial growth factor, (for example the anti-vascular endothelial cell growth factor antibody bevacizumab [AvastinTM], compounds such as those disclosed in International Patent Applications WO 97/22596, WO 97/30035, WO 97/32856 and WO 98/13354) and compounds that work by other mechanisms (for example linomide, inhibitors of integrin $\alpha\text{v}\beta 3$ function and angiostatin);

(vi) vascular damaging agents such as Combretastatin A4 and compounds disclosed in International Patent Applications WO99/02166, WO00/40529, WO00/41669, WO01/92224, WO02/04434 and WO02/08213;

(vii) antisense therapies, for example those which are directed to the targets listed above,
5 such as ISIS 2503, an anti-ras antisense;

(viii) gene therapy approaches, including for example approaches to replace aberrant genes such as aberrant p53 or aberrant BRCA1 or BRCA2, GDEPT (gene-directed enzyme pro-drug therapy) approaches such as those using cytosine deaminase, thymidine kinase or a bacterial
10 nitroreductase enzyme and approaches to increase patient tolerance to chemotherapy or radiotherapy such as multi-drug resistance gene therapy; and

(ix) immunotherapy approaches, including for example ex-vivo and in-vivo approaches to increase the immunogenicity of patient tumour cells, such as transfection with cytokines such as interleukin 2, interleukin 4 or granulocyte-macrophage colony stimulating factor, approaches to decrease T-cell anergy, approaches using transfected immune cells such as cytokine-transfected
15 dendritic cells, approaches using cytokine-transfected tumour cell lines and approaches using anti-idiotypic antibodies.

In a still further aspect, the present invention provides the use of a compound of formula (I), or a pharmaceutically acceptable salt or solvate thereof, as hereinbefore defined in the manufacture of a medicament for the treatment of human diseases or conditions in which
20 modulation of CRTh2 receptor activity is beneficial.

In the context of the present specification, the term "therapy" also includes "prophylaxis" unless there are specific indications to the contrary. The terms "therapeutic" and "therapeutically" should be construed accordingly.

The invention still further provides a method of treating diseases mediated by PGD2 or its
25 metabolites wherein the prostanoid binds to its receptor (especially CRTh2) receptor, which comprises administering to a patient a therapeutically effective amount of a compound of formula (I), or a pharmaceutically acceptable salt, solvate or prodrug thereof, as hereinbefore defined.

The invention also provides a method of treating an inflammatory disease, especially
30 psoriasis, in a patient suffering from, or at risk of, said disease, which comprises administering to

the patient a therapeutically effective amount of a compound of formula (I), or a pharmaceutically acceptable salt or solvate thereof, as hereinbefore defined.

For the above-mentioned therapeutic uses the dosage administered will, of course, vary with the compound employed, the mode of administration, the treatment desired and the disorder indicated.

For the above-mentioned therapeutic uses the dosage administered will, of course, vary with the compound employed, the mode of administration, the treatment desired and the disorder indicated.

The compound of formula (I), prodrugs and pharmaceutically acceptable salts and solvates thereof may be used on their own but will generally be administered in the form of a pharmaceutical composition in which the formula (I) compound/salt/solvate (active ingredient) is in association with a pharmaceutically acceptable adjuvant, diluent or carrier. Depending on the mode of administration, the pharmaceutical composition will preferably comprise from 0.05 to 99 %w (per cent by weight), more preferably from 0.05 to 80 %w, still more preferably from 0.10 to 70 %w, and even more preferably from 0.10 to 50 %w, of active ingredient, all percentages by weight being based on total composition.

The present invention also provides a pharmaceutical composition comprising a compound of formula (I), or a pharmaceutically acceptable salt or solvate thereof, as herein before defined, in association with a pharmaceutically acceptable adjuvant, diluent or carrier.

The pharmaceutical compositions may be administered topically (e.g. to the lung and/or airways or to the skin) in the form of solutions, suspensions, heptafluoroalkane aerosols and dry powder formulations; or systemically, e.g. by oral administration in the form of tablets, capsules, syrups, powders or granules, or by parenteral administration in the form of solutions or suspensions, or by subcutaneous administration or by rectal administration in the form of suppositories or transdermally. Preferably the compound of the invention is administered orally.

The present invention also provides a pharmaceutical composition comprising a compound of formula (I), or a pharmaceutically acceptable salt or solvate thereof, as herein before defined, in association with a pharmaceutically acceptable adjuvant, diluent or carrier.

The invention will now be illustrated by the following non-limiting examples in which, unless stated otherwise:

(i) the title and sub-titled compounds of the examples and methods were named using the

ACD labs/name program (version 6.0) from Advanced Chemical Development Inc, Canada;

(ii) unless stated otherwise, reverse phase preparative HPLC was conducted using a Symmetry, NovaPak or Ex-Terra reverse phase silica column;

(iii) Flash column chromatography refers to normal phase silica chromatography

(iv) solvents were dried with MgSO_4 or Na_2SO_4

(v) Evaporations were carried out by rotary evaporation *in vacuo* and work-up procedures were carried out after removal of residual solids such as drying agents by filtration;

(vi) Unless otherwise stated, operations were carried out at ambient temperature, that is in the range 18-25°C and under an atmosphere of an inert gas such as argon or nitrogen;

(vii) yields are given for illustration only and are not necessarily the maximum attainable;

(viii) the structures of the end-products of the formula (1) were confirmed by nuclear (generally proton) magnetic resonance (NMR) and mass spectral techniques; proton magnetic resonance chemical shift values were measured on the delta scale and peak multiplicities are shown as follows: s, singlet; d, doublet; t, triplet; m, multiplet; br, broad; q, quartet, quin, quintet;

(ix) intermediates were not generally fully characterised and purity was assessed by thin layer chromatography (TLC), high-performance liquid chromatography (HPLC), mass spectrometry (MS), infra-red (IR) or NMR analysis;

(x) mass spectra (MS): generally only ions which indicate the parent mass are reported when given, ^1H NMR data is quoted in the form of delta values for major diagnostic protons, given in parts per million (ppm) relative to tetramethylsilane (TMS) as an internal standard;

(xi) the following abbreviations are used:

dec decomposed

DMF *N,N*-Dimethyl formamide

EtOAc Ethylacetate

h hour

NMP *N*-methylpyrrolidine

RT ROOM TEMPERATURE

TFA trifluoroacetic acid

THF tetrahydrofuran

Examples**Example 1****3-(4-Chlorophenoxy)-5-fluoro-2-methyl-1H-indole-1-acetic acid****(i) 3-(4-Chlorophenoxy)-5-fluoro-2-methyl-1H-indole**

5 1-(4-Chloro-phenoxy)-propan-2-one (2.05 g) was added to a stirred solution of (4-fluoro-phenyl)-hydrazine (1.4 g) in ethanol (30 ml) at RT. After 2h, the solvent was removed under reduced pressure and the residue dissolved in DCM (30 ml). Phosphorus trichloride (1.06 ml) was added dropwise to the solution and after stirring at RT for 16h the reaction was quenched with aq. sodium hydrogencarbonate solution. The mixture was extracted with DCM, the
10 organics washed with water, dried and evaporated under reduced pressure. The residue was purified by chromatography on silica eluting with 20% ethylacetate/iso-hexane. Yield 0.75 g
MS: ESI (-ve): 274/6 (M-1)

(ii) 3-(4-Chlorophenoxy)-5-fluoro-2-methyl-1H-indole-1-acetic acid, ethyl ester

15 Sodium hydride (60 % disp. in oil) (0.12 g) was added portionwise to a stirred solution of the product from step (i) (0.75 g) in DMF (10 ml) at RT. After 10 min, ethylbromoacetate (345 ul) was added, the mixture stirred at RT for 3h then quenched with water and extracted with diethylether. The organics were washed with water, dried and evaporated under reduced
20 pressure. The residue was purified by chromatography on silica eluting with 15 % ethylacetate/iso-hexane. Yield 0.38 g
MS: APCI (-ve): 360/2 (M-1)

(iii) 3-(4-Chlorophenoxy)-5-fluoro-2-methyl-1H-indole-1-acetic acid

25 A solution of 2M sodium hydroxide (3 ml) was added to a stirred mixture of the product from step (ii) (0.36 g), water (10 ml) and THF (10 ml). After 2 h the solution was acidified with 2M hydrochloric acid and extracted with diethylether. The organics were washed with water, dried and evaporated under reduced pressure. The residue was recrystallised from diethylether/isohexane. Yield 138 mg
¹H NMR DMSO-d₆: δ 13.10 (1H, s) ; 7.51 (1H, dd) ; 7.37-7.33 (2H, m) ; 6.98-6.83 (4H, m) ;
30 5.02 (2H, s) ; 2.19 (3H, s).
MS: APCI (-ve): 332/4 (M-1)

Mpt. 198°C

Example 2

5-Fluoro-2-methyl-3-[4-(methylsulfonyl)phenoxy]-1*H*-indole-1-acetic acid

(i) 1-[4-(Methylthio)phenoxy]-2-propanone

A mixture of chloroacetone (10 ml), potassium carbonate (21 g), and 4-(methylthio)phenol (10 g) in acetone (200 ml) was heated under reflux for 6 h. The solvent was removed under reduced pressure and the residue partitioned between diethylether/water. The organics were separated, dried and evaporated under reduced pressure. The residue was purified by chromatography on silica eluting with 5-10 % ethylacetate/iso-hexane. Yield 12.43 g.

¹H NMR CDCl₃: δ 7.26 (2H, d) ; 6.83 (2H, d) ; 4.52 (2H, s) ; 2.45 (3H, s) ; 2.28 (3H, s)

(ii) 5-Fluoro-2-methyl-3-[4-(methylthio)phenoxy]-1*H*-indole

A mixture of the product from step (i) (3.63 g) and 4-fluorohydrazine hydrochloride (2 g) in acetic acid (40 ml) were heated at 90°C for 2 h, cooled, and the solvent removed under reduced pressure. The residue was partitioned between diethylether/water, the organics were separated, washed with aq sodium hydroxide solution, water, dried and evaporated under reduced pressure. The residue was purified by chromatography on silica eluting with 10 % ethylacetate/iso-hexane. Yield 0.34 g

MS: ESI (-ve): 286 (M-1)

(iii) 5-Fluoro-2-methyl-3-[4-(methylthio)phenoxy]-1*H*-indole-1-acetic acid, ethyl ester

A mixture of the product from step (ii) (335 mg), potassium carbonate (0.3 g) and ethyl bromoacetate (0.16 ml) in DMF (5 ml) was stirred at RT. After 16 h, ethyl bromoacetate (0.1 ml) and potassium carbonate (0.15 g) were added and the mixture heated at 50°C for 4 h then partitioned between diethylether/water. The organics were washed with water, dried and evaporated under reduced pressure. The residue was purified by chromatography on silica eluting with 10 % ethylacetate/iso-hexane. Yield 0.41 g

MS: ESI (-ve): 372 (M-1)

(iv) 5-Fluoro-2-methyl-3-[4-(methylsulfonyl)phenoxy]-1*H*-indole-1-acetic acid, ethyl ester

3-Chloroperoxybenzoic acid (0.6 g) was added to a solution of the product from step (iii) (0.4 g) in DCM (10 ml) at RT. After 2.5 h the mixture was partitioned between DCM/aq. sodium metabisulphite solution, the organics washed with aq. sodium hydrogencarbonate solution, water, dried and evaporated under reduced pressure. The residue was purified by chromatography on silica eluting with 30 % ethylacetate/iso-hexane. Yield 0.2 g

(v) 5-Fluoro-2-methyl-3-[4-(methylsulfonyl)phenoxy]-1*H*-indole-1-acetic acid

The title compound was prepared by the method of example 1 step (iii) using the product from step (iv). Yield 0.075 g

¹H NMR DMSO-d₆: δ 13.12 (1H, s) ; 7.88 (2H, d) ; 7.54 (1H, dd) ; 7.10 (2H, d) ; 7.01-6.96 (1H, m) ; 6.91-6.88 (1H, m) ; 5.05 (2H, s) ; 3.18 (3H, s) ; 2.2 (3H, s)

MS: APCI (-ve): 376 (M-1)

Mpt. 204-7°C

Example 3

3-(4-Chlorophenoxy)-2-methyl-4-[(methylsulfonyl)amino]-1*H*-indole-1-acetic acid

(i) (2-Bromo-5-nitrophenyl)-hydrazine

To 2-bromo-5-nitro-aniline (5 g) in conc hydrochloric acid (50 ml) at 0°C was added a solution of sodium nitrite (1.45 g) in water (20 ml). After 1 h, a solution of tin dichloride (8.73 g) in conc hydrochloric acid (15 ml) was added. The reaction was stirred for 30 min at 0°C and 1 h at room temperature. The resulting solid was filtered off and recrystallised from hot ethanol. Yield 2.9 g.

¹H NMR DMSO-d₆: δ 7.92 (1H, d) ; 7.88 (1H, d) ; 7.71 (1H, dd)

(ii) 7-Bromo-3-(4-chlorophenoxy)-2-methyl-4-nitro-1*H*-indole

A mixture of the compound from (i) (2.4 g) and 1-(4-Chloro-phenoxy)-propan-2-one (1.65 g) in MeCN (20 ml) and water (5 ml) was stirred for 16 h. The volatiles were removed *in vacuo*. AcOH (50 ml) was added and the reaction heated at 75°C for 72 h. The volatiles were evaporated under reduced pressure and the residue was purified by chromatography on silica eluting with 5 % ethylacetate/iso-hexane. Yield 0.34 g

¹H NMR CDCl₃: δ 7.92 (1H, d); 8.43 (1H, s); 7.82 (1H, d), 7.39 (1H, d), 7.19 (2H, d), 6.79 (1H, d), 2.40 (3H, s)

(iii) 7-Bromo-3-(4-chlorophenoxy)-2-methyl-4-nitro-1*H*-indole-1-acetic acid 1,1-dimethylethyl ester

Sodium hydride (60% disp. in oil) (0.043 g) was added to a stirred solution of the product from step (ii) (0.34 g) in THF (4 ml) at RT. After 1 h, *tert*-butylbromoacetate (170 μ l) was added, the mixture stirred at RT for 16 h then quenched with water and extracted with diethylether. The organics were dried and evaporated under reduced pressure. The residue was purified by chromatography on silica eluting with 10 % diethylether/iso-hexane. Yield 0.192 g

¹H NMR CDCl₃: δ 7.63 (1H, d), 7.38 (1H, d), 7.19 (2H, d), 6.78 (2H, d), 5.29 (2H, s), 2.26 (3H, s), 1.48 (9H, s)

(iv) 4-Amino-3-(4-chlorophenoxy)-2-methyl-1*H*-indole-1-acetic acid, 1,1-dimethylethyl ester

To a solution of the product from step (iii) (0.18 g) in EtOAc (30 ml) was added triethylamine (0.15 ml) and 5% Pt/ C (36 mg) and the reaction stirred under hydrogen (1 atm) for 2 h. The reaction was filtered through celite and the filtrate evaporated under reduced pressure. Yield 0.139 g.

¹H NMR CDCl₃: δ 7.21 (2H, d), 6.97 (1H, t), 6.91 (2H, d), 6.62 (1H, d), 6.27 (1H, d), 4.62 (2H, s), 3.94 (2H, bs), 2.15 (3H, s), 1.44 (9H, s)

(v) 3-(4-Chlorophenoxy)-2-methyl-4-[(methylsulfonyl)amino]-1*H*-indole-1-acetic acid, 1,1-dimethylethyl ester

To a solution of the product from step (iv) (70 mg) in MeCN (1 ml) was added triethylamine (50 μ l) and methanesulfonyl chloride (24 μ l) and the reaction stirred at 50°C for 3 h. The residue was partitioned between diethylether/water, the organics were separated, washed with aq potassium hydrogensulfate solution, brine, dried and evaporated under reduced pressure. The residue was purified by chromatography on silica eluting with 5-30% ethylacetate/iso-hexane. Yield 42 mg

¹H NMR CDCl₃: δ 7.28 - 7.23 (3H, m), 7.16 (1H, t), 7.04 (1H, d), 6.91 (2H, d), 6.84 (1H, s), 4.69 (2H, s), 2.66 (3H, s), 2.20 (3H, s), 1.46 (9H, s)

(vi) 3-(4-Chlorophenoxy)-2-methyl-4-[(methylsulfonyl)amino]-1H-indole-1-acetic acid

A solution of 1M sodium hydroxide (0.5 ml) was added to a stirred mixture of the product from step (v) (40 mg) in THF (1 ml). After 3 h, further 1M sodium hydroxide (1 ml) was added and the reaction heated at 55°C for 16 h. Water (10 ml) was added and the THF evaporated under reduced pressure. The solution was acidified with 2M hydrochloric acid and the resulting solid filtered off and dried. Yield 24 mg

¹H NMR DMSO-d₆: δ 8.54 (1H, s), 7.37 - 7.32 (3H, m), 7.08 (1H, t), 6.93 (1H, d), 6.87 (2H, d), 4.99 (2H, s), 2.70 (3H, s), 2.13 (3H, s)

MS: APCI (-ve): 407 (M-1)

Example 4**4-(Acetylamino)-3-(4-chlorophenoxy)-2-methyl-1H-indole-1-acetic acid****(i) 4-(Acetylamino)-3-(4-chlorophenoxy)-2-methyl-1H-indole-1-acetic acid, 1,1-dimethylethyl ester**

To a solution of the product from example 3 step (iv) (70 mg) in MeCN (1 ml) was added triethylamine (50 µl) and acetyl chloride (17 µl) and the reaction stirred at 50°C for 3 h. The residue was partitioned between diethylether/water, the organics were separated, washed with aq potassium hydrogensulfate solution, brine, dried and evaporated under reduced pressure. The residue was purified by chromatography on silica eluting with 5-30% ethylacetate/iso-hexane.

Yield 51 mg

¹H NMR CDCl₃: δ 7.90 (1H, d), 7.89 (1H, s), 7.24 (2H, d), 7.16 (1H, t), 6.97 (1H, d), 6.91 (2H, d), 4.67 (2H, s), 2.18 (3H, s), 1.89 (3H, s), 1.43 (9H, s)

(ii) 4-(Acetylamino)-3-(4-chlorophenoxy)-2-methyl-1H-indole-1-acetic acid

The title compound was prepared by the method of example 3 step (vi) using the product from step (i). Yield 0.035 g

¹H NMR DMSO-d₆: δ 9.01 (1H, s), 7.32 (2H, d), 7.26 (2H, d), 7.05 (2H, m), 6.84 (2H, d), 5.00 (2H, s), 2.16 (3H, s), 1.67 (3H, s)

MS: APCI (-ve): 371 (M-1)

Example 5**3-(4-chlorophenoxy)-2-methyl-5-(methylsulfonyl)-1H-indole-1-acetic acid****(i) 3-(4-chlorophenoxy)-2-methyl-5-(methylthio)-1H-indole**

1-(4-Chloro-phenoxy)-propan-2-one (2.66 g) was added to a stirred solution of [4-(methylthio)phenyl]-hydrazine hydrochloride (2.5 g) in MeCN (15 ml) / HCl (0.5M, 15 ml) at RT. The reaction was stirred at 50°C for 1 h. After cooling to room temperature, the reaction was partitioned between ethylacetate/water, the organics were separated, washed with aq sodium hydroxide (1 M), dried and evaporated under reduced pressure. The residue was purified by chromatography on silica eluting with 5-20% ethylacetate/iso-hexane. The resulting hydrazone was dissolved in THF (80 ml). Sodium bicarbonate solid (1.04 g) was added followed by phosphorus trichloride (0.41 ml) dropwise, and the reaction stirred at RT for 2 h. Further phosphorus trichloride (1.20 ml) was added dropwise, and the reaction stirred at RT for 16 h. The reaction was quenched with water. The mixture was extracted with ethylacetate, the organics washed with aq. sodium hydrogencarbonate, brine, dried and evaporated under reduced pressure. The residue was purified by chromatography on silica eluting with 5-10 % ethylacetate/iso-hexane. Yield 0.45 g.

¹H NMR DMSO-d₆: δ 11.09 (1H, s), 7.39 (2H, d), 7.34 (1H, d), 7.10 (1H, dd), 7.06 (1H, s), 6.97 (2H, d), 2.44 (3H, s), 2.29 (3H, s).

(ii) 3-(4-chlorophenoxy)-2-methyl-5-(methylthio)-1H-indole-1-acetic acid, methyl ester

A mixture of the product from step (i) (0.45 g), potassium carbonate (0.415 g) and methyl bromoacetate (0.21 ml) in DMF (3 ml) was stirred at 50°C for 3 h. The reaction was partitioned between ethylacetate/water. The organics were washed with water, dried and evaporated under reduced pressure. The residue was purified by chromatography on silica eluting with 5-15 % ethylacetate/iso-hexane. Yield 0.33 g

¹H NMR DMSO-d₆: δ 7.46 (1H, d), 7.36 (2H, d), 7.10 (1H, dd), 7.03 (1H, d), 6.91 (2H, d), 5.14 (2H, s), 3.70 (3H, s), 2.39 (3H, s), 2.17 (3H, s).

(iii) 3-(4-chlorophenoxy)-2-methyl-5-(methylsulfonyl)-1H-indole-1-acetic acid, methyl ester

To the product from step (ii) (0.32 g) in acetone (4 ml) and water (4 ml) was added solid sodium bicarbonate (0.57 g) followed by oxone (0.69 g in water (2.5 ml)) and the reaction was stirred for 3 h. The reaction was quenched with sodium bisulfite and partitioned between ethylacetate/water. The organics were dried and evaporated under reduced pressure. The residue was purified by chromatography on silica eluting with 30-60% ethylacetate/iso-hexane. Yield 0.24 g

¹H NMR DMSO-d₆: δ 7.78 (1H, d), 7.67 (2H, m), 7.38 (2H, d), 6.94 (2H, d), 5.28 (2H, s), 3.72 (3H, s), 3.15 (3H, s), 2.24 (3H, s).

(iv) 3-(4-Chlorophenoxy)-2-methyl-5-(methylsulfonyl)-1H-indole-1-acetic acid

A solution of 1M sodium hydroxide (1 ml) was added to a stirred mixture of the product from step (iii) (235 mg) in THF (1 ml). After 2 h, water (10 ml) was added and the solution extracted with DCM. The solution was acidified with 2 M hydrochloric acid and extracted with ethylacetate. These later organics were dried and evaporated under reduced pressure. Yield 135 mg

¹H NMR DMSO-d₆: δ 7.79 (1H, d), 7.68 (1H, s), 7.65 (1H, d), 7.37 (2H, d), 6.94 (2H, d), 5.15 (2H, s), 3.15 (3H, s), 2.25 (3H, s).

MS: APCI (-ve): 411 (M+NH₄-1)

Example 6

3-(4-chlorophenoxy)-2-methyl-5-(trifluoromethyl)-1H-indole-1-acetic acid

(i) 3-(4-Chlorophenoxy)-2-methyl-5-(trifluoromethyl)-1H-indole

1-(4-Chloro-phenoxy)-propan-2-one (1.05 g) was added to a stirred solution of (4-trifluoromethyl-phenyl)-hydrazine (1 g) in methanol (8 ml) at RT. After 16h, the solvent was removed under reduced pressure and the residue triturated with iso-hexane to give a hydrazone as a beige solid. This was dissolved in THF (60 ml). Sodium bicarbonate solid (1.43 g) was added followed by phosphorus trichloride (1.26 ml) dropwise, and the reaction stirred at RT for 16 h. The reaction was quenched with aq. sodium hydrogencarbonate solution (100 ml). The mixture was extracted with ethylacetate, the organics washed with sodium hydrogencarbonate solution, brine, dried and evaporated under reduced pressure. The residue was purified by recrystallisation from diethylether/iso-hexane. Yield 1 g

¹H NMR DMSO-d₆: δ 11.51 (1H, s), 7.52 (1H, d), 7.38 (2H, m), 7.35 (2H, d), 6.93 (2H, d), 2.28 (3H, s).

(ii) 3-(4-Chlorophenoxy)-2-methyl-5-(trifluoromethyl)-1H-indole-1-acetic acid, methyl ester

A mixture of the product from step (i) (0.60 g), potassium carbonate (0.516 g) and methyl bromoacetate (0.26 ml) in DMF (4 ml) was stirred at 50°C for 4 h. The reaction was partitioned between ethylacetate/water. The organics were washed with water, dried and evaporated under reduced pressure. The residue was purified by chromatography on silica eluting with 10-20 % ethylacetate/iso-hexane. Yield 0.44 g

¹H NMR DMSO-d₆: δ 7.74 (1H, d), 7.40 (2H, m), 7.37 (2H, d), 6.93 (2H, d), 5.26 (2H, s), 3.72 (3H, s), 2.23 (3H, s).

(iii) 3-(4-chlorophenoxy)-2-methyl-5-(trifluoromethyl)-1H-indole-1-acetic acid

The title compound was prepared by the method of example 5 step (iv) using the product from step (ii). Yield 0.27 g

¹H NMR DMSO-d₆: δ 13.18 (1H, s), 7.74 (1H, d), 7.43 (2H, m), 7.37 (2H, d), 6.93 (2H, d), 5.12 (2H, s), 2.23 (3H, s).

MS: APCI (-ve): 382 (M-1).

Example 7

3-(4-Chlorophenoxy)-2-methyl-5-[(methylsulfonyl)amino]-1H-indole-1-acetic acid

(i) 3-(4-Chlorophenoxy)-2-methyl-5-nitro-1H-indole-1-acetic acid, methyl ester

1-(4-Chloro-phenoxy)-propan-2-one (3.62 g) was added to a stirred solution of (4-nitro-phenyl)-hydrazine (3 g) in methanol (125 ml)/DCM (100 ml) at RT. After 16h, the solvent was removed under reduced pressure to give a hydrazone as a yellow solid. This was dissolved in THF (200 ml). Sodium bicarbonate solid (9.88 g) was added followed by phosphorus trichloride (5.22 ml) dropwise, and the reaction stirred at RT for 10 min and then heated at 60°C for 16 h. After cooling to RT, the bulk of the solvent was removed, and the reaction quenched with water. The mixture was extracted with ethylacetate, the organics dried and evaporated under reduced pressure. The residue was dissolved in DCM, filtered through Celite, and evaporated under

reduced pressure to give 3-(4-chlorophenoxy)-2-methyl-5-nitro-1*H*-indole as a beige solid. This was reacted with methyl bromoacetate by the method of example 6 step (ii) to give the crude sub-titled product. This was purified by chromatography on silica eluting with 30-40 % ethylacetate/iso-hexane. Yield 2.39 g.

¹H NMR DMSO-d₆: δ 8.02 (1H, s), 7.94 (1H, d), 7.39 (2H, d), 6.97 (2H, d), 6.60 (1H, s), 5.31 (2H, s), 3.73 (3H, s), 2.25 (3H, s).

(ii) 5-Amino-3-(4-chlorophenoxy)-2-methyl-1*H*-indole-1-acetic acid, methyl ester

The sub title compound was prepared by the method of example 3 step (iv) using the product from step (i). Yield 2.18 g

¹H NMR DMSO-d₆: δ 7.34 (2H, d), 7.11 (1H, d), 6.90 (2H, d), 6.46 (1H, dd), 6.26 (1H, d), 4.98 (2H, s), 4.42 (2H, s), 3.68 (3H, s), 2.12 (3H, s).

(iii) 3-(4-Chlorophenoxy)-2-methyl-5-[(methylsulfonyl)amino]-1*H*-indole-1-acetic acid

To a solution of the product from step (ii) (0.688 g) in MeCN (5 ml) was added triethylamine (1.39 ml) and methanesulfonyl chloride (0.54 ml) and the reaction stirred at rt for 5 h. Further triethylamine (0.83 ml) and methanesulfonyl chloride (0.54 ml) were added and the reaction stirred for 16 h. The residue was partitioned between ethylacetate/water, the organics were separated, washed with 2M hydrochloric acid, sodium hydrogencarbonate solution, brine, dried and evaporated under reduced pressure. The residue was purified by chromatography on silica eluting with 30-40% ethylacetate/iso-hexane to give a mixture of mono- and di-methanesulfonamides. This was dissolved in THF (2 ml) and a solution of 1 M sodium hydroxide (4 ml) was added and the reaction heated at 55°C for 2 h.. After cooling to RT, water (10 ml) was added and the solution extracted with ethylacetate. The aqueous solution was acidified with 2M hydrochloric acid and extracted with ethylacetate. These later organics were dried and evaporated under reduced pressure. Yield 302 mg

¹H NMR DMSO-d₆: δ 13.07 (1H, s), 9.26 (1H, s), 7.46 (1H, d), 7.35 (2H, d), 7.02 (1H, dd), 6.99 (1H, s), 6.91 (2H, d), 5.00 (2H, s), 2.82 (3H, s), 2.18 (3H, s).

MS: APCI (-ve): 407 (M-1).

Example 8**3-(4-Chlorophenoxy)-5-[(ethylsulfonyl)aminol]-2-methyl-1H-indole-1-acetic acid**

The title compound was prepared by the method of example 7 step (iii) using ethanesulfonyl chloride and the product from example 7 step (ii). Yield 155 mg

5 ¹H NMR DMSO-d₆: δ 13.08 (1H, s), 9.36 (1H, s), 7.44 (1H, d), 7.35 (2H, d), 7.01 (1H, dd), 6.97 (1H, d), 6.91 (2H, d), 4.98 (2H, s), 2.90 (2H, q), 2.18 (3H, s), 1.13 (3H, t).

MS: APCI (-ve): 421 (M-1).

Example 9**3-(4-Carboxyphenoxy)-5-fluoro-2-methyl-1H-indole-1-acetic acid****(i) Methyl 4-[(2Z)-2-[(4-fluorophenyl)hydrazono]propyl]oxy]-benzoate**

Methyl 4-(2-oxopropoxy)benzoate (6.21 g) was added to a solution of 4-fluorophenylhydrazine (2.88 g) in ethanol (50 ml). After 1.5 h the precipitate was collected, washed with ethanol and isohexane and dried to give the sub-title compound (3.72 g).

15 MS: ESI (+ve): 317 [M+H]⁺ 100%

(ii) Methyl 4-[(5-fluoro-2-methyl-1H-indol-3-yl)oxy]-benzoate

Phosphorus trichloride (0.7 ml) was added to a solution of the product from step a) (3.72 g) in THF (120 ml) and the mixture was stirred for 3 days. Aq sodium bicarbonate was added and the mixture was extracted with ethyl acetate. The organic extracts were dried (MgSO₄), evaporated and purified by chromatography (silica, petrol – ether and petrol – ethyl acetate as eluents) to give the sub-title compound (2.17 g).

MS: ESI (+ve and -ve): 300 [M+H]⁺ 100% and 298 [M-H]⁻ 100%

25 (iii) 1,1-Dimethylethyl 5-fluoro-3-[4-(methoxycarbonyl)phenoxy]-2-methyl-1H-indole-1-acetate

Potassium *tert*-butoxide (8.1 ml of 1 M solution in THF) was added to a solution of the product from step b) (2.24 g) and *tert*-butyl bromoacetate in THF (10 ml) at 0 °C. Further potassium *tert*-butoxide (4 ml) was added after 1 h and stirred for a further 1 h. Aq ammonium chloride was added and the mixture was extracted with ethyl acetate. The organic extracts were dried

(MgSO₄), evaporated and purified by chromatography (silica, petrol – ether as eluent) to give the sub-title compound (2.41 g).

MS: ESI (-ve): 412 [M-H]⁻ 100 %

5 **(iv) 3-(4-Carboxyphenoxy)-5-fluoro-2-methyl-1*H*-indole-1-acetic acid**

A solution of the product from step c) (2.41 g) and lithium hydroxide (517 mg) in THF (15 ml), methanol (4 ml) and water (4 ml) was stirred for 30 h. The mixture was acidified with 2M HCl and the mixture was extracted with ethyl acetate. The organic extracts were dried (MgSO₄), and evaporated to give a solid. Crystallisation from *iso*-hexane – acetone gave the title compound as
10 an off-white solid (1.51 g). M.p 227-8 °C.

¹H NMR DMSO-d₆: δ 12.91 (2H, s), 7.91 (2H, d), 7.52 (1H, dd), 7.00-6.93 (3H, m), 6.86 (1H, dd), 5.04 (2H, s) 2.20 (3H, s).

MS: ESI (+ve): 341 [M+H]⁺ 100%

15 **Example 10**

5-Fluoro-2-methyl-3-[4-[(methylamino)carbonyl]phenoxy]- 1*H*-indole-1-acetic acid

(i) Methyl 5-Fluoro-2-methyl-3-[4-[(methylamino)carbonyl]phenoxy]- 1*H*-indole-1-acetate

HATU (294 mg) was added to a solution of the product from Example 9 (208 mg) and Hunig's base (0.3 ml) in NMP (1.2 ml). After 10 min a solution of methylamine in THF (0.4 ml, 2M) was
20 added and stirred for 20 h. 2M HCl (1 ml) was added and the mixture was extracted with ethyl acetate. The organic extracts were dried (MgSO₄), evaporated, re-dissolved in methanol and treated with a solution of trimethylsilyldiazomethan (1 ml, 2M in ether). Evaporation and purification by chromatography (silica, petrol – acetone as eluent) gave the sub-title compound (177 mg).

25 MS: ESI (+ve and -ve): 371 [M+H]⁺ 100% and 369 [M-H]⁻ 100%

(ii) 5-Fluoro-2-methyl-3-[4-[(methylamino)carbonyl]phenoxy]- 1*H*-indole-1-acetic acid

A solution of the product from step a) (146 mg) and sodium hydroxide (0.4 ml, 1M) in THF (2 ml) – MeOH (1 ml) was stirred for 18 h. The solvent was removed *in vacuo* and the residue was
30 washed with ether, acidified (2M HCl) and extracted with ethyl acetate. The organic extracts

were dried (MgSO_4), evaporated and crystallised from *isohexane* – acetone to give the title compound as a white solid (53 mg). M.p. 217-8 °C.

MS: ESI (+ve and -ve): 357 $[\text{M}+\text{H}]^+$ 100% and 355 $[\text{M}-\text{H}]^-$ 100%

^1H NMR DMSO- d_6 : δ 13.10 (1H, s), 8.29 (1H, d), 7.78 (2H, d), 7.52 (1H, dd), 6.99-6.91 (3H, m), 6.83 (1H, d), 5.04 (2H, s), 2.75 (3H, d), 2.19 (3H, s).

Example 11

3-[4-[(Ethylamino)carbonyl]phenoxy]-5-fluoro-2-methyl-1H-indole-1-acetic acid

(iii) Methyl 3-[4-[(Ethylamino)carbonyl]phenoxy]-5-fluoro-2-methyl-1H-indole-1-acetate

The sub-title compound was prepared by the method of Example 10, step a) using the product from Example 9 and ethylamine in THF.

MS: ESI (+ve): 384 $[\text{M}+\text{H}]^+$ 100 %.

(iv) 3-[4-[(Ethylamino)carbonyl]phenoxy]-5-fluoro-2-methyl-1H-indole-1-acetic acid

The title compound was prepared by the method of Example 10, step b) using the product from step a). M.p. 220-2 °C

MS: ESI (+ve): 370 $[\text{M}+\text{H}]^+$ 100 %.

^1H NMR DMSO- d_6 : δ 13.09 (1H, s), 8.33 (1H, d), 7.79 (2H, d), 7.52 (1H, dd), 6.99-6.91 (3H, m), 6.83 (1H, d), 5.04 (2H, s), 3.26 (2H, dq), 2.19 (3H, s), 1.10 (3H, t).

Example 12

5-Fluoro-2-methyl-3-[4-[(1-methylethyl)amino]carbonyl]phenoxy]-1H-indole-1-acetic acid

(i) Methyl 5-fluoro-2-methyl-3-[4-[(1-methylethyl)amino]carbonyl]phenoxy]- 1H-indole-1-acetic acid

The sub-title compound was prepared by the method of Example 10, step a) using the product from Example 9 and *isopropylamine*.

MS: ESI (+ve): 399 $[\text{M}+\text{H}]^+$ 100 %.

(ii) 5-Fluoro-2-methyl-3-[4-[(1-methylethyl)amino]carbonyl]phenoxy]- 1H-indole-1-acetic acid.

The title compound was prepared by the method of Example 10, step b) using the product from step a). M.p. 218-9 °C.

MS: ESI (+ve): 385 [M+H]⁺ 100 %.

¹H NMR DMSO-d₆: δ 13.09 (1H, s), 8.07 (1H, d), 7.80 (2H, d), 7.52 (1H, dd), 6.99-6.91 (3H, m), 6.82 (1H, d), 5.04 (2H, s), 4.07 (1H, d heptet), 2.19 (3H, s), 1.10 (6H, d).

Example 13

3-(4-Carboxyphenoxy)-5-chloro-2-methyl-1H-indole-1-acetic acid

(i) Methyl 4-[(2Z)-2-[(4-fluorophenyl)hydrazono]propyl]oxy]-benzoate

The sub-title compound was prepared from 4-chlorophenylhydrazine by the method of Example 9 step a).

MS: ESI (+ve): 317 [M+H]⁺ 100 %

(ii) Methyl 4-[(5-chloro-2-methyl-1H-indol-3-yl)oxy]- benzoate

The sub-title compound was prepared from the product of step a) by the method of Example 9 step b).

MS: ESI (-ve): 314 [M-H]⁻ 100 %

(iii) 1,1-Dimethylethyl 5-chloro-3-[4-(methoxycarbonyl)phenoxy]-2-methyl-1H-indole-1-acetate

The sub-title compound was prepared from the product of step b) by the method of Example 9 step c).

MS: ESI (-ve): 428 [M-H]⁻ 100 %

(iv) 3-(4-Carboxyphenoxy)-5-chloro-2-methyl-1H-indole-1-acetic acid

A solution of the product from step c) (1.65 g) and sodium hydroxide (8.5 ml, 1M) in THF (15 ml) and methanol (10 ml) was stirred for 30 h. The solvent was removed *in vacuo*, the mixture was acidified with 2M HCl and extracted with ethyl acetate. The organic extracts were dried (MgSO₄), and evaporated to give a solid. Crystallisation from *iso*-hexane – acetone gave the title compound as an off-white solid (1.51 g). M.p. 215-6 °C.

¹H NMR DMSO-d₆: δ 12.94 (1H, s), 7.91 (2H, d), 7.56 (1H, dd), 7.13 (1H, d), 7.21 (1H, s), 6.98 (2H, d), 5.06 (2H, s) 2.20 (3H, s).

MS: ESI (+ve): 358 [M+H]⁺ 100%

5 **Example 14**

5-Fluoro-3-[4-(methoxycarbonyl)phenoxy]-2-methyl-1H-indole-1-acetic acid

A solution of the product from Example 9 step c) (128 mg) in TFA (2 ml) and DCM (1 ml) was stirred for 2h. The mixture was evaporated and purified by chromatography (silica, DCM–

MeOH - AcOH as eluent) to give, after trituration with ether, the title compound (41 mg). M.p.

10 195-6 °C.

MS: ESI (+ve): 358 [M+H]⁺ 100 %.

¹H NMR DMSO-d₆: δ 13.09 (1H, s), 7.93 (2H, d), 7.53 (1H, dd), 7.02-6.94 (3H, m), 6.85 (1H, d), 5.04 (2H, s), 3.81 (3H, s), 2.19 (3H, s).

15 **Example 15**

5-Chloro-3-[4-(methoxycarbonyl)phenoxy]-2-methyl-1H-indole-1-acetic acid

The title compound was prepared from the product from Example 13 step c) by the method of Example 14. M.p. 196-7 °C.

MS: ESI (+ve): 374 [M+H]⁺ 100 %.

20 ¹H NMR DMSO-d₆: δ 13.14 (1H, s), 7.94 (2H, d), 7.56 (1H, dd), 7.15-7.10 (2H, m), 7.00 (2H, d), 5.04 (2H, s), 3.81 (3H, s), 2.19 (3H, s).

Example 16

5-Chloro-2-methyl-3-[4-[(methylamino)carbonyl]phenoxy]- 1H-indole-1-acetic acid

25 **(i) Methyl 5-chloro-2-methyl-3-[4-[(methylamino)carbonyl]phenoxy]- 1H-indole-1-acetate**

The sub-title compound was prepared by the method of Example 10, step a) using the product from Example 13 and methylamine in THF.

MS: ESI (+ve): 384 [M+H]⁺ 100 %

30 **(ii) 5-Chloro-2-methyl-3-[4-[(methylamino)carbonyl]phenoxy]- 1H-indole-1-acetic acid**

The title compound was prepared by the method of Example 10, step b) using the product from step a). M.p. 225 °C (dec).

MS: ESI (+ve): 373 [M+H]⁺ 100 %.

¹H NMR DMSO-d₆: δ 8.30 (1H, d), 7.79 (2H, d), 7.55 (1H, dd), 7.12 (1H, d), 7.09 (1H, s), 6.94 (2H, d), 5.05 (2H, s), 2.76 (3H, s), 2.20 (3H, s).

Example 17

5-Chloro-3-[4-[(ethylamino)carbonyl]phenoxy]-2-methyl-1H-indole-1-acetic acid

(i) Methyl 5-chloro-3-[4-[(ethylamino)carbonyl]phenoxy]-2-methyl-1H-indole-1-acetate

The sub-title compound was prepared by the method of Example 10, step a) using the product from Example 13 and ethylamine in THF.

MS: ESI (+ve): 401 [M+H]⁺ 100 %

(ii) 5-Chloro-3-[4-[(ethylamino)carbonyl]phenoxy]-2-methyl-1H-indole-1-acetic acid

The title compound was prepared by the method of Example 10, step b) using the product from step a). M.p. 220 °C (dec).

MS: ESI (+ve): 387 [M+H]⁺ 100 %.

¹H NMR DMSO-d₆: δ 7.81 (2H, d), 7.56 (1H, dd), 7.13 (1H, d), 7.08 (1H, s), 6.94 (2H, d), 5.05 (2H, s), 3.26 (2H, dq), 2.20 (3H, s), 1.10 (3H, t).

Example 18

Sodium 5-Chloro-2-methyl-3-[4-[(1-methylethyl)amino]carbonyl]phenoxy]-1H-indole-1-acetate

(i) Methyl 5-chloro-2-methyl-3-[4-[(1-methylethyl)amino]carbonyl]phenoxy]-1H-indole-1-acetate

The sub-title compound was prepared by the method of Example 10, step a) using the product from Example 13 and *isopropylamine*.

MS: ESI (+ve): 415 [M+H]⁺ 100 %

(ii) Sodium 5-Chloro-2-methyl-3-[4-[(1-methylethyl)amino]carbonyl]phenoxy]-1H-indole-1-acetate

A solution of the product from step a) (102 mg) and sodium hydroxide (0.25 ml, 1M) in THF (2 ml) – MeOH (3 ml) was stirred for 2 days. The solvent was removed *in vacuo* and the residue was washed with ether, and water, collected, and dried to give the title compound as a white solid (71 mg). M.p. < 275 °C

5 MS: ESI (+ve): 401 [M+H]⁺ 100 %.

¹H NMR DMSO-d₆: δ 8.09 (1H, d), 7.79 (2H, d), 7.35 (1H, dd), 7.03-7.00 (2H, m), 6.93 (2H, d), 4.41 (2H, s), 4.07 (1H, d heptet), 2.17 (3H, s), 1.14 (6H, d).

Example 19

10 **3-[4-[[[(2-Aminoethyl)amino]carbonyl]phenoxy]-5-fluoro-2-methyl-1H-indole-1-acetic acid**

(i) Methyl 3-[4-[[[2-[[[(1,1-dimethylethoxy)hydroxymethyl]amino]ethyl]amino] carbonyl] phenoxy]-5-fluoro-2-methyl-1H-indole-1-acetate

The sub-title compound was prepared by the method of Example 10, step a) using the product from Example 13 and 1,1-dimethylethyl 3-aminopropylcarbamate.

15 MS: ESI (-ve): 588 [M+AcO]⁻ 100 %

¹H NMR CDCl₃: δ 7.79 (2H, d), 7.24 (1H, s), 7.14 (2H, s), 7.10 (1H, s), 6.97 (2H, d), 4.89 (1H, s), 4.80 (2H, s), 3.77 (3H, s), 3.49 (2H, q), 3.24 (2H, q), 2.26 (3H, s), 1.70 (1H, tt), 1.45 (9H, s).

20 **(ii) 3-[4-[[[2-[[[(1,1-Dimethylethoxy)hydroxymethyl]amino]ethyl]amino]carbonyl] phenoxy]-5-fluoro-2-methyl-1H-indole-1-acetic acid**

A solution of the product from step a) 9121 mg) in TFA (1 ml) and DCM (1 ml) was stirred for 2 h. The solvent was removed *in vacuo*, aq sodium bicarbonate was added and the mixture was extracted with ethyl acetate (3 times) and DCM (3 times). The organic extracts were dried (MgSO₄ and, evaporated to give the sub-title compound (95 mg).

25 MS: ESI (+ve): 430 [M+H]⁺ 100 %.

(iii) 3-[4-[[[(2-Aminoethyl)amino]carbonyl]phenoxy]-5-fluoro-2-methyl-1H-indole-1-acetic acid

The title compound was prepared by the method of Example 10, step b) using the product from step b).

30 MS: ESI (+ve): 416 [M+H]⁺ 100 %.

¹H NMR DMSO-d₆: δ 8.44 (1H, t), 7.81 (2H, d), 7.56 (1H, dd), 7.13 (1H, d), 7.08 (1H, s), 6.94 (2H, d), 5.05 (2H, s), 3.26 (2H, dq), 2.20 (3H, s), 1.10 (3H, t).

Example 20

5 2,5-Dimethyl-3-[4-(methylsulfonyl)phenoxy]-1H-indole-1-acetic acid

(i) 1-[4-(Methylsulfonyl)phenoxy]-2-propanone

3-Chloroperoxybenzoic acid (5.7 g) was added portionwise to a solution of the product from example 2 step (i) (1.8 g) in DCM (100 ml) and the reaction stirred for 2 h. The mixture was washed with 10% aqueous sodium metabisulphite, saturated sodium bicarbonate, water and
10 brine, dried (MgSO₄), filtered and evaporated *in vacuo*. The residue was purified by chromatography on silica eluting with 50% ethylacetate/iso-hexane. Yield 600 mg.

¹H NMR DMSO-d₆ δ 7.90 (d, 2H), 7.29 (d, 2H), 5.87 (s, 2H), 2.09 (s, 3H)

MS: APCI (+ve): 229 (M+1).

15 (ii) 1-[4-(Methylsulfonyl)phenoxy]-2-propanone, (4-methylphenyl)hydrazone

The product from step (i) (1 g) and 4-methylphenylhydrazine (540 mg) were dissolved in ethanol (50 ml) and stirred for 1 h. The mixture was evaporated and azeotroped with toluene to give a brown solid. Yield 1.2 g.

MS: APCI (+ve): 333 (M+1).

20

(iii) 2,5-Dimethyl-3-[4-(methylsulfonyl)phenoxy]-1H-indole

Phosphorous trichloride (200 μl) was added to a solution of the product from step (ii) (1.1 g) in THF (50 ml) and the reaction stirred for 20 h. The mixture was diluted with EtOAc (100 ml), washed with water, saturated sodium bicarbonate and brine, dried (MgSO₄), filtered and
25 evaporated *in vacuo*. The residue was purified by chromatography on silica eluting with 50% ethylacetate/iso-hexane. Yield 530 mg.

¹H NMR DMSO-d₆ δ 10.90 (s, 1H), 7.85 (d, 2H), 7.22 (d, 1H), 7.09 (d, 2H), 6.88 (d, 1H), 6.87 (s, 1H), 3.17 (s, 3H), 2.28 (s, 3H), 2.22 (s, 3H)

MS: APCI (+ve): 316 (M+1).

30

(iv) 2,5-Dimethyl-3-[4-(methylsulfonyl)phenoxy]-1H-indole-1-acetic acid

Sodium t-butoxide (220 mg) was added to a solution of the product from step (iii) (600 mg) in THF (20 ml) and stirred for 10 min. Ethyl bromoacetate (250 μ l) was added and the reaction stirred for a further 1 h. The mixture was then diluted with water (10 ml), 1M aqueous sodium hydroxide (5 ml) added and stirred for 3 h. The mixture was extracted with EtOAc, washed with brine, dried (MgSO_4), filtered and evaporated. The residue was purified using reverse phase preparative chromatography (eluent $\text{MeCN}/\text{NH}_3(\text{aq})$) to give the title compound. Yield 450 mg. ^1H NMR DMSO-d_6 δ 7.85 (d, 2H), 7.27 (d, 1H), 7.10 (d, 2H), 6.90 (d, 1H), 6.89 (s, 1H), 4.62 (s, 2H), 3.17 (s, 3H), 2.29 (s, 3H), 2.15 (s, 3H). MS: APCI (-ve): 372 (M-1).

Example 21

2-Methyl-3-[4-(methylsulfonyl)phenoxy]-5-(trifluoromethyl)-1H-indole-1-acetic acid

(i) 1-[4-(Methylsulfonyl)phenoxy]-2-propanone, [4-(trifluoromethyl) phenyl]hydrazone

The sub-title compound was prepared by the method of example 20 step (ii), using the product from example 20 step (i) (600 mg) and 4-(trifluoromethyl)phenylhydrazine (460 mg). Yield 1.0 g.

MS: APCI (+ve): 387 (M+1).

(ii) 2-Methyl-3-[4-(methylsulfonyl)phenoxy]-5-(trifluoromethyl)-1H-indole

The sub-title compound was prepared by the method of example 20 step (iii), using the product from step (i) (800 mg). Yield 520 mg.

^1H NMR DMSO-d_6 δ 11.61 (s, 1H), 7.87 (d, 2H), 7.55 (d, 1H), 7.45 (s, 1H), 7.13 (d, 2H), 6.95 (d, 1H), 3.18 (s, 3H), 2.29 (s, 3H).

MS: APCI (+ve): 370 (M+1).

(iii) 2-Methyl-3-[4-(methylsulfonyl)phenoxy]-5-(trifluoromethyl)-1H-indole-1-acetic acid

The title compound was prepared by the method of example 20 step (iv), using the product from step (ii) (500 mg). Yield 320 mg.

^1H NMR DMSO-d_6 δ 7.87 (d, 2H), 7.61 (d, 1H), 7.44 (s, 1H), 7.36 (d, 1H), 7.12 (d, 2H), 4.61 (s, 2H), 3.18 (s, 3H), 1.75 (s, 3H).

MS: APCI (-ve): 426 (M-1)

Example 22**5-Chloro- α ,2-dimethyl-3-[4-(methylsulfonyl)phenoxy]-1H-indole-1-acetic acid****(i) 1-[4-(Methylsulfonyl)phenoxy]-2-propanone, (4-chlorophenyl)hydrazone**

5 The sub-title compound was prepared by the method of example 20 step (ii), using the product from example 20 step (i) (700 mg) and 4-chlorophenylhydrazine (430 mg). Yield 900 mg.

^1H NMR DMSO- d_6 δ 9.26 (s, 1H), 7.85 (d, 2H), 7.10 (d, 2H), 7.23 (d, 2H), 7.21 (d, 2H), 4.76 (s, 2H), 3.32 (s, 3H), 1.96 (s, 3H)

MS: APCI (+ve): 353 (M+1).

10

(ii) 5-Chloro-2-methyl-3-[4-(methylsulfonyl)phenoxy]-1H-indole

The sub-title compound was prepared by the method of example 20 step (iii), using the product from step (i) (800 mg). Yield 450 mg.

^1H NMR DMSO- d_6 δ 11.32 (s, 1H), 7.87 (d, 2H), 7.36 (d, 1H), 7.09 (m, 4H), 3.18 (s, 3H), 2.25 (s, 3H)

15

MS: APCI (+ve): 370 (M+1).

(iii) 5-Chloro-2-methyl-3-[4-(methylsulfonyl)phenoxy]-1H-indole-1-acetic acid

20 The title compound was prepared by the method of example 20 step (iv), using the product from step (ii) (350 mg). Yield 300 mg.

^1H NMR DMSO- d_6 δ 7.86 (d, 2H), 7.43 (d, 1H), 7.09 (m, 4H), 4.61 (s, 2H), 3.18 (s, 3H), 2.17 (s, 3H)

MS: APCI (-ve): 393 (M-1)

Example 23**5-Cyano-2-methyl-3-[4-(methylsulfonyl)phenoxy]-1H-indole-1-acetic acid****(i) 4-[2-[1-Methyl-2-[4-(methylsulfonyl)phenoxy]ethylidene]hydrazino]-benzonitrile**

The sub-title compound was prepared by the method of example 20 step (ii), using the product from example 20 step (i) (700 mg) and 4-cyanophenylhydrazine (400 mg). Yield 900 mg.

30 MS: APCI (+ve): 344 (M+1).

(ii) 2-Methyl-3-[4-(methylsulfonyl)phenoxy]-1*H*-indole-5-carbonitrile

The sub-title compound was prepared by the method of example 20 step (iii), using the product from step (i) (450 mg). Yield 320 mg.

¹H NMR DMSO-d₆ δ 7.87 (d, 2H), 7.64 (s, 1H), 7.52 (d, 1H), 7.44 (d, 1H), 7.12 (d, 2H), 3.18 (s, 3H), 2.28 (s, 3H)

MS: APCI (+ve): 327 (M+1).

(iii) 5-Cyano-2-methyl-3-[4-(methylsulfonyl)phenoxy]-1*H*-indole-1-acetic acid

The title compound was prepared by the method of example 20 step (iv), using the product from step (ii) (270 mg). Yield 150 mg.

¹H NMR DMSO-d₆ δ 7.88 (d, 2H), 7.70 (d, 1H), 7.68 (s, 1H), 7.48 (d, 1H), 7.11 (d, 2H), 4.97 (s, 2H), 3.18 (s, 3H), 2.22 (s, 3H)

MS: APCI (-ve): 383 (M-1)

Example 24**3-(4-Chlorophenoxy)-4-[(ethylsulfonyl)amino]-2-methyl-1*H*-indole-1-acetic acid****(i) 1-(4-Chlorophenoxy)-2-propanone, (3-nitrophenyl)hydrazone**

3-Nitrophenylhydrazine hydrochloride (25.0 g) was stirred in a mixture of EtOAc and aqueous sodium bicarbonate for 30 min. The layers were separated, the aqueous extracted with EtOAc and the combined extracts (1000 ml) washed with brine, dried (MgSO₄) and filtered. Ethanol (200 ml) was added to the filtrate, followed by 1-(4-chlorophenoxy)-propan-2-one (23.9 g) and stirred for 5 h. The mixture was evaporated and the residue treated with ether/isohexane (1:1) to give a light brown solid. Yield 30.0 g.

MS: APCI (+ve): 320 (M+1).

(ii) 3-(4-Chlorophenoxy)-2-methyl-4-nitro-1*H*-indole

The product from step (i) (29.0 g) was dissolved in THF (1000 ml), sodium bicarbonate (75.6 g) added, followed by phosphorous trichloride (37.1 ml) and heated at 70°C for 20 h. The reaction was cooled to RT, diluted with EtOAc (1000 ml), washed with water and brine, dried (MgSO₄), filtered and evaporated. The residue was purified by chromatography on silica eluting with 20% ethylacetate/iso-hexane. Yield 6 g.

¹H NMR DMSO-d₆ δ 7.83 (d, 1H), 7.77 (d, 1H), 7.29 (d, 2H), 7.23 (t, 1H), 6.80 (d, 2H), 2.28 (s, 3H)

MS: APCI (+ve): 303 (M+1).

5 **(iii) 3-(4-Chlorophenoxy)-2-methyl-4-nitro-1*H*-indole-1-acetic acid, ethyl ester**

The product from step (ii) (6.0 g) was dissolved in THF (100 ml), sodium t-butoxide (2.1 g) added, stirred for 10 min, ethyl bromoacetate (2.45 ml) added and stirred for a further 20 min.

The reaction was quenched with 1M hydrochloric acid, extracted with EtOAc, washed with brine, dried (MgSO₄), filtered and evaporated. The residue was purified by chromatography on silica eluting with 20% ethylacetate/iso-hexane. Yield 6 g.

¹H NMR DMSO-d₆ δ 8.02 (d, 1H), 7.86 (d, 1H), 7.32 (d, 2H), 7.30 (t, 1H), 6.80 (d, 2H), 5.33 (s, 2H), 4.18 (q, 2H), 2.23 (s, 3H), 1.22 (t, 3H)

MS: APCI (+ve): 389 (M+1).

15 **(iv) 4-Amino-3-(4-chlorophenoxy)-2-methyl-1*H*-indole-1-acetic acid, ethyl ester**

The product from step (iii) (1.0 g) was dissolved in EtOAc (20 ml), triethylamine (1.1 ml) added, followed by 5% Pt/C (50 mg) and hydrogenated at 1 atm and RT for 6 h. The catalyst was filtered off and the filtrate evaporated to give a light brown solid. Yield 800 mg.

¹H NMR DMSO-d₆ δ 7.36 (d, 2H), 6.93 (d, 2H), 6.80 (t, 1H), 6.62 (d, 1H), 6.15 (d, 1H), 4.97 (s, 2H), 4.68 (s, 2H), 4.15 (q, 2H), 2.07 (s, 3H), 1.20 (t, 3H)

MS: APCI (+ve): 359 (M+1).

(v) 3-(4-Chlorophenoxy)-4-[(ethylsulfonyl)amino]-2-methyl-1*H*-indole-1-acetic acid

The product from step (iv) (250 mg) was dissolved in CH₃CN (10 ml). Triethylamine (300 μl) added, followed by ethanesulphonyl chloride (170 μl) and the mixture stirred for 20 h. The reaction was then diluted with MeOH (5 ml), 1M sodium hydroxide (2.1 ml) added and stirred for 5 h. The mixture was diluted with water, acidified with 2M hydrochloric acid, extracted with EtOAc, dried (MgSO₄) and evaporated. The residue was purified using reverse phase preparative chromatography (eluent MeCN/NH₃(aq)) to give the title compound. Yield 190 mg.

¹H NMR DMSO-d₆ δ 7.33 (d, 2H), 7.28 (d, 1H), 7.03 (t, 1H), 6.88 (d, 2H), 6.88 (d, 1H), 4.80 (s, 2H), 2.88 (q, 2H), 2.11 (s, 3H), 1.04 (t, 3H)

MS: APCI (-ve): 421 (M-1)

Example 25

3-(4-Chlorophenoxy)-4-[[[(dimethylamino)sulfonyl]amino]-2-methyl-1H-indole-1-acetic acid

5 The title compound was prepared by the method of example 25 step (v), using the product from example 25 step (iv) (250 mg) and dimethylsulfamoyl chloride and heating at 60°C. Yield 80 mg.

¹H NMR DMSO-d₆ δ 7.33 (d, 2H), 7.24 (d, 1H), 7.02 (t, 1H), 6.95 (d, 1H), 6.89 (d, 2H), 4.85 (s, 2H), 2.55 (s, 6H), 2.11 (s, 3H)

10 MS: APCI (-ve): 436 (M-1)

Example 26

3-(4-Chlorophenoxy)-2-methyl-4-pyrazinyl-1H-indole-1-acetic acid

(i) 3-(4-Chlorophenoxy)-4-iodo-2-methyl-1H-indole-1-acetic acid, ethyl ester

15 The product from example 25 step (iv) (1.5 g) was treated with 10% aqueous sulphuric acid (50 ml) and cooled to 0°C. A solution of sodium nitrite (350 mg) in water (3 ml) was added dropwise and the reaction stirred for 15 min. A solution of potassium iodide (2.1 g) in water (5 ml) was added all at once and the reaction allowed to attain RT over 1 h. The mixture was extracted with EtOAc, washed with aqueous sodium thiosulphate, water and brine, dried
20 (MgSO₄), filtered and evaporated. The residue was purified by chromatography on silica eluting with 20% ethylacetate/iso-hexane. Yield 280 mg.

¹H NMR CDCl₃ δ 7.52 (d, 1H), 7.21 (d, 1H), 7.21 (d, 2H), 6.89 (t, 1H), 6.82 (d, 2H), 4.79 (s, 2H), 4.22 (q 2H), 2.21 (s, 3H), 1.26 (t, 3H)

MS: APCI (+ve): 470 (M+1).

(ii) 3-(4-Chlorophenoxy)-2-methyl-4-pyrazinyl-1H-indole-1-acetic acid

25 The product from step (i) (250 mg), 2-(tributylstannyl)-pyrazine (260 mg), Pd (dba)₂ (30 mg) and triphenyl-arsine (210 mg) were dissolved in toluene (4 ml) and heated at 90°C for 20 h. The reaction was cooled to RT, methanol (10 ml) added, followed by 1M aqueous sodium hydroxide
30 (2 ml) and stirred for 20 h. The mixture was diluted with water, extracted with EtOAc, washed with brine, dried (MgSO₄), filtered and evaporated. The residue was purified using reverse

phase preparative chromatography (eluent MeCN/NH₃(aq)) to give the title compound. Yield 30 mg.

¹H NMR DMSO-d₆ δ 8.69 (s, 1H), 8.44 (m, 1H), 8.41 (d, 1H), 7.64 (d, 1H), 7.26 (t, 1H), 7.20 (d, 1H), 7.08 (d, 2H), 6.42 (d, 2H), 5.07 (s, 2H), 2.20 (s, 3H)

MS: APCI (-ve): 392 (M-1)

Example 27

3-(4-Chlorophenoxy)-2-methyl-4-[[[(1-methylethyl)sulfonyl]amino]-1H-indole-1-acetic acid

The product from example 25 step (iv) (250 mg) was dissolved in pyridine (2 ml), treated with 2-propanesulfonyl chloride (200 μl) and heated at 50°C for 5 h. The reaction was acidified with 2M hydrochloric acid, extracted with EtOAc, washed with water and brine, dried (MgSO₄), filtered and evaporated. The residue was dissolved in methanol (10 ml), treated with 1M sodium hydroxide (2 ml) and stirred for 5 h. The mixture was diluted with water, acidified with 2M hydrochloric acid, extracted with EtOAc, washed with brine, dried (MgSO₄), filtered and evaporated. The residue was purified using reverse phase preparative chromatography (eluent MeCN/NH₃(aq)) to give the title compound. Yield 30 mg.

¹H NMR DMSO-d₆ δ 7.34 (d, 2H), 7.28 (d, 1H), 7.04 (t, 1H), 6.92 (d, 1H), 6.88 (d, 2H), 4.88 (s, 2H), 3.13 (m, 1H), 2.11 (s, 3H), 1.11 (d, 6H)

MS: APCI (-ve): 435 (M-1)

Example 28

3-[4-[(Dimethylamino)sulfonyl]phenoxy]-5-fluoro-2-methyl-1H-indole-1-acetic acid

(i) *N,N*-Dimethyl-4-(2-oxopropoxy)-benzenesulfonamide

The sub-title compound was prepared by the method of example 2 step (i) using 4-hydroxy-*N,N*-dimethylbenzenesulfonamide (4.3 g). Yield 4.2 g.

¹H NMR DMSO-d₆ δ 7.66 (d, 2H), 7.12 (d, 2H), 3.32 (s, 2H), 2.57 (s, 6H), 2.17 (s, 3H)

MS: APCI (+ve): 258 (M+1).

(ii) 4-[[[(2-[(4-Fluorophenyl)hydrazono]propyl]oxy)-*N,N*-dimethyl- benzenesulfonamide

The sub-title compound was prepared by the method of example 20 step (ii), using the product from step (i) (1.6 g) and 4-fluorophenylhydrazine (800 mg). Yield 2.2 g.

MS: APCI (+ve): 366 (M+1).

(iii) 4-[(5-Fluoro-2-methyl-1*H*-indol-3-yl)oxy]-*N,N*-dimethyl- benzenesulfonamide

The sub-title compound was prepared by the method of example 20 step (iii), using the product from step (ii) (2.0 g). Yield 500 mg.

¹H NMR DMSO-d₆ δ 11.18 (s, 1H), 7.70 (d, 2H), 7.33 (m, 1H), 7.11 (d, 2H), 6.90 (m, 1H), 6.83 (d, 1H), 2.59 (s, 6H), 2.25 (s, 3H)

MS: APCI (+ve): 349 (M+1).

(iv) 3-[4-[(Dimethylamino)sulfonyl]phenoxy]-5-fluoro-2-methyl-1*H*-indole-1-acetic acid

The title compound was prepared by the method of example 20 step (iv), using the product from step (iii) (270 mg). Yield 80 mg.

¹H NMR DMSO-d₆ δ 7.70 (d, 2H), 7.50 (m, 1H), 7.11 (d, 2H), 6.95 (m, 1H), 6.88 (d, 1H), 4.94 (s, 2H), 2.59 (s, 6H), 2.19 (s, 3H)

MS: APCI (-ve): 405 (M-1)

Example 29

3-[4-(Ethylsulfonyl)phenoxy]-5-fluoro-2-methyl-1*H*-indole-1-acetic acid

(i) 1-[4-(Ethylthio)phenoxy]-2-propanone

The sub-title compound was prepared by the method of example 2 step (i) using 4-(ethylthio)phenol (20.0 g). Yield 21.2 g.

¹H NMR DMSO-d₆ δ 7.29 (d, 2H), 6.87 (d, 2H), 4.80 (s, 2H), 2.85 (q, 2H), 2.15 (s, 3H), 1.16 (t, 3H)

MS: APCI (+ve): 211 (M+1).

(ii) 1-[4-(Ethylthio)phenoxy]- 2-propanone, (4-fluorophenyl)hydrazone

The sub-title compound was prepared by the method of example 20 step (ii), using the product from step (i) (1.6 g) and 4-fluorophenylhydrazine (1.0 g). Yield 2.4 g.

MS: APCI (+ve): 319 (M+1).

¹H NMR DMSO-d₆ δ 7.30 (d, 2H), 7.09 (m, 2H), 7.03 (d, 2H), 6.98 (d, 2H), 4.61 (s, 2H), 2.85 (q, 2H), 1.94 (s, 3H), 1.16 (t, 3H)

MS: APCI (+ve): 319 (M+1).

(iii) 3-[4-(Ethylthio)phenoxy]-5-fluoro-2-methyl-1*H*-indole

The sub-title compound was prepared by the method of example 20 step (iii), using the product
5 from step (ii) (890 mg). Yield 800 mg.

MS: APCI (+ve): 302 (M+1).

(iv) 3-[4-(Ethylsulfonyl)phenoxy]-5-fluoro-2-methyl-1*H*-indole

3-Chloroperoxybenzoic acid (1.14 g) was added portionwise to a solution of the product from
10 step (iii) (800 mg) in DCM (20 ml) and the reaction stirred for 1 h. The mixture was evaporated
and purified by chromatography on silica eluting with 25% ethylacetate/iso-hexane. Yield 200
mg.

¹H NMR DMSO δ 11.19 (s, 1H), 7.82 (d, 2H), 7.34 (m, 1H), 7.11 (d, 2H), 6.91 (m, 1H), 6.83
(d, 1H), 3.24 (q, 2H), 2.25 (s, 3H), 1.10 (t, 3H)

15 MS: APCI (+ve): 334 (M+1).

(v) 3-[4-(Ethylsulfonyl)phenoxy]-5-fluoro-2-methyl-1*H*-indole-1-acetic acid

The title compound was prepared by the method of example 20 step (iv), using the product from
step (iv) (160 mg). Yield 130 mg.

20 ¹H NMR DMSO-d₆ δ 7.81 (d, 2H), 7.43 (m, 1H), 7.12 (d, 2H), 6.91 (m, 1H), 6.85 (d, 1H), 4.71
(s, 2H), 3.23 (q, 2H), 2.18 (s, 3H), 1.10 (t, 3H)

MS: APCI (-ve): 390 (M-1)

Example 30

25 **3-[4-(Ethylsulfonyl)phenoxy]-2-methyl-5-(trifluoromethyl)-1*H*-indole-1-acetic acid**

(i) 1-[4-(ethylthio)phenoxy]-2-propanone, [4-(trifluoromethyl) phenyl]hydrazone

The sub-title compound was prepared by the method of example 20 step (ii), using the product
from example 30 step (i) (2.1 g) and 4-(trifluoromethyl)phenylhydrazine (1.7 g). Yield 3.5 g.

MS: APCI (+ve): 369 (M+1).

30 **(ii) 3-[4-(Ethylthio)phenoxy]-2-methyl-5-(trifluoromethyl)-1*H*-indole**

The sub-title compound was prepared by the method of example 20 step (iii), using the product from step (i) (3.2 g). Yield 1.5 g.

MS: APCI (+ve): 352 (M+1).

5 **(iii) 3-[4-(Ethylsulfonyl)phenoxy]-2-methyl-5-(trifluoromethyl)-1*H*-indole**

A solution of oxone (1.0 g) in water (30ml) was added to a solution of the product from step (ii) (1.4 g) in acetonitrile (100 ml) and stirred for 2 h. Further oxone (500 mg) was added and the reaction stirred for a further 3 h. The mixture was evaporated to ~50 ml, extracted with EtOAc, washed with aqueous sodium metabisulphite and brine, dried (MgSO₄), filtered and evaporated.

10 The residue was purified by chromatography on silica eluting with 30% ethylacetate/iso-hexane. Yield 1.2 g.

¹H NMR DMSO-d₆ δ 11.61 (s, 1H), 7.83 (d, 2H), 7.55 (d, 1H), 7.44 (s, 1H), 7.38 (d, 1H), 7.14 (d, 2H), 3.24 (q, 2H), 2.29 (s, 3H), 1.10 (t, 3H)

MS: APCI (+ve): 384 (M+1).

15 **(iv) 3-[4-(Ethylsulfonyl)phenoxy]-2-methyl-5-(trifluoromethyl)-1*H*-indole-1-acetic acid**

The title compound was prepared by the method of example 20 step (iv), using the product from step (iii) (1.1 g). Yield 380 mg.

¹H NMR DMSO δ 7.83 (d, 2H), 7.66 (d, 1H), 7.45 (s, 1H), 7.39 (d, 1H), 7.14 (d, 2H), 4.83 (s, 2H), 3.24 (q, 2H), 2.22 (s, 3H), 1.09 (t, 3H)

MS: APCI (-ve): 440 (M-1)

Example 31

3-(4Cyanophenoxy)-2-methyl-5-(trifluoromethyl)-1*H*-indole-1-acetic acid

25 **(i) 4-(2-Oxopropoxy)benzonitrile**

The sub-title compound was prepared by the method of example 2 step (i) using 4-hydroxybenzonitrile (15.5 g). Yield 22.5 g.

¹H NMR DMSO-d₆ δ 7.75 (d, 2H), 7.08 (d, 2H), 4.98 (s, 2H), 2.15 (s, 3H)

MS: APCI (+ve): 174 (M+1).

30 **(ii) 4-[[2-[[4-(Trifluoromethyl)phenyl]hydrazono]propyl]oxy]benzonitrile**

The sub-title compound was prepared by the method of example 20 step (ii), using the product from step (i) (3.8 g) and 4-(trifluoromethyl)phenylhydrazine (3.7 g). Yield 2.8 g.

¹H NMR DMSO-d₆ δ 9.61 (s, 1H), 7.78 (d, 2H), 7.51 (d, 2H), 7.23 (d, 2H), 7.19 (d, 2H), 4.78 (s, 2H), 2.00 (s, 3H)

5 MS: APCI (+ve): 334 (M+1).

(iii) 4-[[2-Methyl-5-(trifluoromethyl)-1H-indol-3-yl]oxy]-benzonitrile

The sub-title compound was prepared by the method of example 20 step (iii), using the product from step (ii) (2.6 g). Yield 1.7 g.

10 ¹H NMR DMSO-d₆ δ 11.61 (s, 1H), 7.80 (d, 2H), 7.55 (d, 1H), 7.42 (s, 1H), 7.38 (d, 1H), 7.08 (d, 2H), 2.29 (s, 3H)

MS: APCI (+ve): 317 (M+1).

(iv) 3-(4-Cyanophenoxy)-2-methyl-5-(trifluoromethyl)-1H-indole-1-acetic acid

15 The title compound was prepared by the method of example 20 step (iv), using the product from step (iii) (1.4 g). Yield 720 mg.

¹H NMR DMSO-d₆ δ 7.80 (d, 2H), 7.62 (d, 1H), 7.42 (s, 1H), 7.36 (d, 1H), 7.07 (d, 2H), 4.66 (s, 2H), 2.20 (s, 3H)

MS: APCI (-ve): 373 (M-1).

20

Example 32

3-(4-Cyanophenoxy)-5-fluoro-2-methyl-1H-indole-1-acetic acid

(i) 4-[[2-[(4-Fluorophenyl)hydrazono]propyl]oxy]benzonitrile

25 The sub-title compound was prepared by the method of example 20 step (ii), using the product from example 32 step (i) (3.8 g) and 4-fluorophenylhydrazine (2.7 g). Yield 2.9 g.

¹H NMR DMSO-d₆ δ 9.10 (s, 1H), 7.78 (d, 2H), 7.18 (d, 2H), 7.05 (m, 4H), 4.73 (s, 2H), 1.94 (s, 3H)

MS: APCI (+ve): 284 (M+1).

30 **(ii) 4-[(5-Fluoro-2-methyl-1H-indol-3-yl)oxy]benzonitrile**

The sub-title compound was prepared by the method of example 20 step (iii), using the product from step (i) (2.8 g). Yield 1.4 g.

^1H NMR DMSO- d_6 δ 11.20 (s, 1H), 7.78 (d, 2H), 7.34 (m, 1H), 7.05 (d, 2H), 6.91 (m, 1H), 6.81 (d, 1H), 2.24 (s, 3H)

5 MS: APCI (+ve): 267 (M+1).

(iii) 3-(4-Cyanophenoxy)-5-fluoro-2-methyl-1*H*-indole-1-acetic acid

The title compound was prepared by the method of example 20 step (iv), using the product from step (ii) (1.2 g). Yield 430 mg.

10 ^1H NMR DMSO- d_6 δ 7.78 (d, 2H), 7.38 (m, 1H), 7.05 (d, 2H), 6.89 (m, 1H), 6.81 (d, 1H), 4.52 (s, 2H), 2.15 (s, 3H)

MS: APCI (-ve): 323 (M-1).

Pharmacological Data

15 Ligand Binding Assay

[^3H]PGD₂ was purchased from Perkin Elmer Life Sciences with a specific activity of 100-210Ci/mmol. All other chemicals were of analytical grade.

HEK cells expressing rhCRTh2 / G α 16 were routinely maintained in DMEM containing
20 10% Foetal Bovine Serum (HyClone), 1mg/ml geneticin, 2mM L-glutamine and 1% non-essential amino acids. For the preparation of membranes, the adherent transfected HEK cells were grown to confluence in two layer tissue culture factories (Fisher, catalogue number TKT-170-070E). Maximal levels of receptor expression were induced by addition of 500mM sodium butyrate for the last 18 hours of culture. The adherent cells were washed once with phosphate
25 buffered saline (PBS, 50ml per cell factory) and detached by the addition of 50ml per cell factory of ice-cold membrane homogenisation buffer [20mM HEPES (pH 7.4), 0.1mM dithiothreitol, 1mM EDTA, 0.1mM phenyl methyl sulphonyl fluoride and 100 μ g/ml bacitracin]. Cells were pelleted by centrifugation at 220xg for 10 minutes at 4°C, re-suspended in half the original volume of fresh membrane homogenisation buffer and disrupted using a Polytron homogeniser
30 for 2 x 20 second bursts keeping the tube in ice at all times. Unbroken cells were removed by centrifugation at 220xg for 10 minutes at 4°C and the membrane fraction pelleted by

centrifugation at 90000xg for 30 minutes at 4°C. The final pellet was re-suspended in 4 ml of membrane homogenisation buffer per cell factory used and the protein content determined.

Membranes were stored at -80°C in suitable aliquots.

All assays were performed in Corning clear bottomed, white 96-well NBS plates (Fisher).

5 Prior to assay, the HEK cells membranes containing CRTh2 were coated onto SPA PVT WGA beads (Amersham). For coating membranes were incubated with beads at typically 25µg membrane protein per mg beads at 4°C with constant agitation overnight. (The optimum coating concentrations were determined for each batch of membranes) The beads were pelleted by centrifugation (800xg for 7minutes at 4°C), washed once with assay buffer (50mM HEPES pH
10 7.4 containing 5mM magnesium chloride) and finally re-suspended in assay buffer at a bead concentration of 10mg/ml.


Each assay contained 20µl of 6.25nM [³H]PGD₂, 20µl membrane saturated SPA beads both in assay buffer and 10µl of compound solution or 13,14-dihydro-15-keto prostaglandin D₂ (DK-PGD₂, for determination of non-specific binding, Cayman chemical company). Compounds and
15 DK-PGD₂ were dissolved in DMSO and diluted in the same solvent to 100x the required final concentration. Assay buffer was added to give a final concentration of 10% DMSO (compounds were now at 10x the required final concentration) and this was the solution added to the assay plate. The assay plate was incubated at room temperature for 2 hours and counted on a Wallac Microbeta liquid scintillation counter (1 minute per well).

20 Compounds of formula (I) have an IC₅₀ value of less than (<) 10µM.

Specifically example 9 has a pIC₅₀ = 6.75, example 5 has a pIC₅₀ = 7.05 and example 6 has a pIC₅₀ 7.95.

Claims

1. A compound of formula (I) or a pharmaceutically acceptable salt or solvate thereof:



(I)

in which

- 10 R^1 is one or more substituents selected from hydrogen, halogen, CN, nitro, SO_2R^4 , OH, OR^4 , $S(O)_xR^4$, $SO_2NR^5R^6$, $CONR^5R^6$, NR^5R^6 , $NR^9SO_2R^4$, $NR^9SO_2NR^5R^6$, $NR^9CO_2R^4$, NR^9COR^4 , aryl, heteroaryl, C_2 - C_6 alkenyl, C_2 - C_6 alkynyl or C_{1-6} alkyl, the latter five groups being optionally substituted by one or more substituents independently selected from halogen, CN, $NR^9SO_2R^4$, $NR^9CO_2R^4$, NR^9COR^4 , OR^8 and NR^5R^6 , $S(O)_xR^7$ where x is 0, 1 or 2;
- 15 R^2 is hydrogen, halogen, CN, SO_2R^4 or $CONR^5R^6$, CH_2OH , CH_2OR^4 or C_{1-7} alkyl, the latter group being optionally substituted by one or more substituents independently selected from halogen atoms, OR^8 and NR^5R^6 , $S(O)_xR^7$ where x is 0, 1 or 2;
- 20 R^3 is aryl or heteroaryl each of which is optionally substituted by one or more substituents independently selected from hydrogen, halogen, CN, nitro, OH, SO_2R^4 , OR^4 , SR^4 , SOR^4 , $SO_2NR^5R^6$, $CONR^5R^6$, NR^5R^6 , $NHSO_2R^4$, $NHCO_2R^4$, $NHCOR^4$, $NR^7SO_2R^4$, $NR^7CO_2R^4$, NR^7COR^4 , NHC_{1-6} alkyl NR^5R^6 , C_2 - C_6 alkenyl, C_2 - C_6 alkynyl, C_{1-6} alkyl, the latter three groups being optionally substituted by one or more substituents independently selected from halogen
- 25 atoms, CN, OR^8 and NR^5R^6 , $S(O)_xR^7$ where x = 0, 1 or 2;

R^4 represents aryl, heteroaryl, or C_{1-6} alkyl all of which may be optionally substituted by one or more substituents independently selected from halogen atoms, aryl, heteroaryl, OR^{10} , OH , $NR^{11}R^{12}$, $S(O)_xR^{13}$ (where $x = 0, 1$ or 2), $CONR^{14}R^{15}$, $NR^{14}COR^{15}$, $SO_2NR^{14}R^{15}$, $NR^{14}SO_2R^{15}$, CN , nitro;

R^5 and R^6 independently represent a hydrogen atom, a C_{1-6} alkyl group, or an aryl, or a heteroaryl, the latter three of which may be optionally substituted by one or more substituents independently selected from halogen atoms, aryl, OR^8 and $NR^{14}R^{15}$, $CONR^{14}R^{15}$, $NR^{14}COR^{15}$, $SO_2NR^{14}R^{15}$, $NR^{14}SO_2R^{15}$; CN , nitro

or

R^5 and R^6 together with the nitrogen atom to which they are attached can form a 3-8 membered saturated heterocyclic ring optionally containing one or more atoms selected from O , $S(O)_x$ where $x = 0, 1$ or 2 , NR^{16} , and itself optionally substituted by C_{1-3} alkyl;

R^7 and R^{13} independently represent a C_1-C_6 , alkyl, an aryl or a heteroaryl group, all of which may be optionally substituted by halogen atoms;

R^8 represents a hydrogen atom, $C(O)R^9$, C_1-C_6 alkyl (optionally substituted by halogen atoms or aryl) an aryl or a heteroaryl group (optionally substituted by halogen);

each of R^9 , R^{10} , R^{11} , R^{12} , R^{14} , R^{15} , independently represents a hydrogen atom, C_1-C_6 alkyl, an aryl or a heteroaryl group (all of which may be optionally substituted by halogen atoms); and

R^{16} is hydrogen, C_{1-4} alkyl, $-COC_{1-4}$ alkyl, $COYC_{1-4}$ alkyl where Y is O or NR^7 .

2. A compound according to claim 1 in which R^1 is hydrogen, halogen, heteroaryl, CF_3 , alkyl, cyano, $CONR^5R^6$, $SO_2NR^5R^6$, SO_2 alkyl, $NR^9SO_2R^4$, NR^9COR^4 , $NR^9SO_2NR^5R^6$.

3. A compound according to claim 1 in which R^1 is hydrogen, chlorine, fluorine, $NHSO_2Me$, $NHSO_2Et$, SO_2Me , CF_3 , $NHCOMe$, pyrazinyl, or $NHSO_2NMe_2$.

4. A compound according to any one of claims 1 to 3 in which R² is C₁₋₆alkyl.

5. A compound according to claim 4 in which R² is methyl.

6. A compound according to any one of claims 1 to 5 in which R³ is phenyl substituted by one or more halogen atoms, CONR⁵R⁶, SO₂NR⁵R⁶, cyano or SO₂R⁴ groups

7. A compound according to any one of claims 1 to 5 in which R³ is phenyl substituted by chlorine or SO₂Me, CONHMe, CONHEt, CONHPr, NH(CH₂)₃NH₂ or cyano.

8. A compound according to any one of claims 1 to 7 selected from:

3-(4-Chlorophenoxy)-5-fluoro-2-methyl-1*H*-indole-1-acetic acid;

5-Fluoro-2-methyl-3-[4-(methylsulfonyl)phenoxy]-1*H*-indole-1-acetic acid;

3-(4-Chlorophenoxy)-2-methyl-4-[(methylsulfonyl)amino]-1*H*-indole-1-acetic acid;

4-(Acetylamino)-3-(4-chlorophenoxy)-2-methyl-1*H*-indole-1-acetic acid;

3-(4-chlorophenoxy)-2-methyl-5-(methylsulfonyl)-1*H*-indole-1-acetic acid;

3-(4-chlorophenoxy)-2-methyl-5-(trifluoromethyl)-1*H*-indole-1-acetic acid;

3-(4-Chlorophenoxy)-2-methyl-5-[(methylsulfonyl)amino]-1*H*-indole-1-acetic acid;

3-(4-Chlorophenoxy)-5-[(ethylsulfonyl)amino]-2-methyl-1*H*-indole-1-acetic acid;

3-(4-Carboxyphenoxy)-5-fluoro-2-methyl-1*H*-indole-1-acetic acid;

5-Fluoro-2-methyl-3-[4-[(methylamino)carbonyl]phenoxy]-1*H*-indole-1-acetic acid;

3-[4-[(Ethylamino)carbonyl]phenoxy]-5-fluoro-2-methyl-1*H*-indole-1-acetic acid;

5-Fluoro-2-methyl-3-[4-[(1-methylethyl)amino]carbonyl]phenoxy]-1*H*-indole-1-acetic acid;

3-(4-Carboxyphenoxy)-5-chloro-2-methyl-1*H*-indole-1-acetic acid;

5-Fluoro-3-[4-(methoxycarbonyl)phenoxy]-2-methyl-1*H*-indole-1-acetic acid;

5-Chloro-3-[4-(methoxycarbonyl)phenoxy]-2-methyl-1*H*-indole-1-acetic acid;

5-Chloro-2-methyl-3-[4-[(methylamino)carbonyl]phenoxy]-1*H*-indole-1-acetic acid;

5-Chloro-3-[4-[(ethylamino)carbonyl]phenoxy]-2-methyl-1*H*-indole-1-acetic acid;


Sodium 5-Chloro-2-methyl-3-[4-[(1-methylethyl)amino]carbonyl]phenoxy]-1*H*-indole-1-

acetate;

3-[4-[(2-Aminoethyl)amino]carbonyl]phenoxy]-5-fluoro-2-methyl-1*H*-indole-1-acetic acid;

2,5-Dimethyl-3-[4-(methylsulfonyl)phenoxy]-1*H*-indole-1-acetic acid;
 2-Methyl-3-[4-(methylsulfonyl)phenoxy]-5-(trifluoromethyl)-1*H*-indole-1-acetic acid;
 5-Chloro- α ,2-dimethyl-3-[4-(methylsulfonyl)phenoxy]-1*H*-indole-1-acetic acid;
 5-Cyano-2-methyl-3-[4-(methylsulfonyl)phenoxy]-1*H*-indole-1-acetic acid;
 5 3-(4-Chlorophenoxy)-4-[(ethylsulfonyl)amino]-2-methyl-1*H*-indole-1-acetic acid;
 3-(4-Chlorophenoxy)-4-[[dimethylamino)sulfonyl]amino]-2-methyl-1*H*-indole-1-acetic acid;
 3-(4-Chlorophenoxy)-2-methyl-4-pyrazinyl-1*H*-indole-1-acetic acid;
 3-(4-Chlorophenoxy)-2-methyl-4-[(1-methylethyl)sulfonyl]amino]-1*H*-indole-1-acetic acid;
 3-[4-[(Dimethylamino)sulfonyl]phenoxy]-5-fluoro-2-methyl-1*H*-indole-1-acetic acid;
 10 3-[4-(Ethylsulfonyl)phenoxy]-5-fluoro-2-methyl-1*H*-indole-1-acetic acid;
 3-[4-(Ethylsulfonyl)phenoxy]-2-methyl-5-(trifluoromethyl)-1*H*-indole-1-acetic acid;
 3-(4-Cyanophenoxy)-2-methyl-5-(trifluoromethyl)-1*H*-indole-1-acetic acid;
 3-(4-Cyanophenoxy)-5-fluoro-2-methyl-1*H*-indole-1-acetic acid;
 and pharmaceutically acceptable salts thereof.

- 15 9. A compound of formula (I) according to any one of claims 1 to 8 for use in therapy.
10. A method of treating a disease mediated by prostaglandin D₂, which comprises administering to a patient a therapeutically effective amount of a compound of formula (I), or a
 20 pharmaceutically acceptable salt as defined in claims 1 to 8.
11. A method of treatment according to claim 10 wherein the disease is asthma or rhinitis.
12. A process for the preparation of a compound of formula (I) which comprises reaction of a
 25 compound of formula (II):



(II)

in which R^1 , R^2 and R^3 are as defined in formula (I) or are protected derivatives thereof, with a compound of formula (IIA):



where R^{17} is an ester forming group and L is a leaving group in the presence of a base, and optionally thereafter in any order:

- removing any protecting group
- 10 • hydrolysing the ester group R^{17} to the corresponding acid
- forming a pharmaceutically acceptable salt or solvate.

INTERNATIONAL SEARCH REPORT

 International Application No
 PCT/GB2004/003502

 A. CLASSIFICATION OF SUBJECT MATTER
 IPC 7 C07D209/36

According to International Patent Classification (IPC) or to both national classification and IPC

B. FIELDS SEARCHED

Minimum documentation searched (classification system followed by classification symbols)

IPC 7 C07D

Documentation searched other than minimum documentation to the extent that such documents are included in the fields searched

Electronic data base consulted during the international search (name of data base and, where practical, search terms used)

EPO-Internal, BEILSTEIN Data, PAJ, WPI Data, CHEM ABS Data

C. DOCUMENTS CONSIDERED TO BE RELEVANT

Category *	Citation of document, with indication, where appropriate, of the relevant passages	Relevant to claim No.
A	US 5 459 150 A (BROOKS DEE W ET AL) 17 October 1995 (1995-10-17) the whole document -----	1-12
A	WO 03/064387 A (HOFFMANN LA ROCHE) 7 August 2003 (2003-08-07) the whole document -----	1-12
A	GB 1 356 834 A (ICI LTD) 19 June 1974 (1974-06-19) cited in the application the whole document -----	1-12
A	WO 01/92224 A (ARNOULD JEAN CLAUDE ; BIRD THOMAS GEOFFREY (FR); ASTRAZENCA UK LTD (G) 6 December 2001 (2001-12-06) the whole document ----- -/--	1-12

☒ Further documents are listed in the continuation of box C.

☒ Patent family members are listed in annex.

* Special categories of cited documents :

- *A* document defining the general state of the art which is not considered to be of particular relevance
- *E* earlier document but published on or after the international filing date
- *L* document which may throw doubts on priority claim(s) or which is cited to establish the publication date of another citation or other special reason (as specified)
- *O* document referring to an oral disclosure, use, exhibition or other means
- *P* document published prior to the international filing date but later than the priority date claimed

- *T* later document published after the international filing date or priority date and not in conflict with the application but cited to understand the principle or theory underlying the invention
- *X* document of particular relevance: the claimed invention cannot be considered novel or cannot be considered to involve an inventive step when the document is taken alone
- *Y* document of particular relevance: the claimed invention cannot be considered to involve an inventive step when the document is combined with one or more other such documents, such combination being obvious to a person skilled in the art.
- *&* document member of the same patent family

Date of the actual completion of the international search

21 October 2004

Date of mailing of the international search report

04/11/2004

Name and mailing address of the ISA

 European Patent Office, P.B. 5818 Patentlaan 2
 NL - 2280 HV Rijswijk
 Tel. (+31-70) 340-2940, Tx. 31 651 epo nl,
 Fax: (+31-70) 340-3015

Authorized officer

Zellner, A

INTERNATIONAL SEARCH REPORT

Int. Patent Application No
PCT/GB2004/003502

C.(Continuation) DOCUMENTS CONSIDERED TO BE RELEVANT

Category *	Citation of document, with indication, where appropriate, of the relevant passages	Relevant to claim No.
P,Y	WO 03/101961 A1 (ASTRAZENECA AB, SWED.) 11 December 2003 (2003-12-11) the whole document -----	1-12
P,Y	WO 2004/007451 A1 (ASTRAZENECA AB, SWED.) 22 January 2004 (2004-01-22) the whole document -----	1-12
P,Y	DATABASE CA 'Online! CHEMICAL ABSTRACTS SERVICE, COLUMBUS, OHIO, US; TANIMOTO, NORIHIKO ET AL: "Preparation of indole derivatives as P6D2 receptor antagonists" XP002301963 retrieved from STN Database accession no. 2003:931327 the whole document & WO 03/097598 A1 (SHIONOGI & CO., LTD., JAPAN) 27 November 2003 (2003-11-27) -----	1-12

INTERNATIONAL SEARCH REPORT

International application No.
PCT/GB2004/003502

Box II Observations where certain claims were found unsearchable (Continuation of item 2 of first sheet)

This International Search Report has not been established in respect of certain claims under Article 17(2)(a) for the following reasons:

1. ☒ Claims Nos.:
because they relate to subject matter not required to be searched by this Authority, namely:
Although claims 10 and 11 are directed to a method of treatment of the human/animal body, the search has been carried out and based on the alleged effects of the compound/composition.
2. ☐ Claims Nos.:
because they relate to parts of the International Application that do not comply with the prescribed requirements to such an extent that no meaningful International Search can be carried out, specifically:
3. ☐ Claims Nos.:
because they are dependent claims and are not drafted in accordance with the second and third sentences of Rule 6.4(a).

Box III Observations where unity of invention is lacking (Continuation of item 3 of first sheet)

This International Searching Authority found multiple inventions in this international application, as follows:

1. ☐ As all required additional search fees were timely paid by the applicant, this International Search Report covers all searchable claims.
2. ☐ As all searchable claims could be searched without effort justifying an additional fee, this Authority did not invite payment of any additional fee.
3. ☐ As only some of the required additional search fees were timely paid by the applicant, this International Search Report covers only those claims for which fees were paid, specifically claims Nos.:
4. ☐ No required additional search fees were timely paid by the applicant. Consequently, this International Search Report is restricted to the invention first mentioned in the claims; it is covered by claims Nos.:

Remark on Protest

- ☐ The additional search fees were accompanied by the applicant's protest.
- ☐ No protest accompanied the payment of additional search fees.

INTERNATIONAL SEARCH REPORT

International Application No

PCT/GB2004/003502

Patent document cited in search report		Publication date	Patent family member(s)	Publication date
US 5459150	A	17-10-1995	US 5095031 A	10-03-1992
			AT 131051 T	15-12-1995
			CA 2090006 A1	21-02-1992
			DE 69115280 D1	18-01-1996
			DE 69115280 T2	13-06-1996
			DK 544819 T3	09-04-1996
			EP 0544819 A1	09-06-1993
			ES 2083595 T3	16-04-1996
			GR 3019198 T3	30-06-1996
			IE 912855 A1	26-02-1992
			JP 6500557 T	20-01-1994
			PT 98710 A ,B	31-07-1992
			WO 9203132 A1	05-03-1992
WO 03064387	A	07-08-2003	CA 2473803 A1	07-08-2003
			WO 03064387 A2	07-08-2003
			US 2003220319 A1	27-11-2003
GB 1356834	A	19-06-1974	AR 198064 A1	31-05-1974
			AR 203626 A1	30-09-1975
			AR 203627 A1	30-09-1975
			AT 328431 B	25-03-1976
			AT 100174 A	15-06-1975
			AT 328432 B	25-03-1976
			AT 100274 A	15-06-1975
			AT 320633 B	25-02-1975
			AU 464145 B2	14-08-1975
			AU 4738172 A	11-04-1974
			BE 790679 A1	27-04-1973
			CA 983932 A1	17-02-1976
			CH 577499 A5	15-07-1976
			CS 178144 B2	31-08-1977
			CS 178120 B2	31-08-1977
			DD 105611 A5	05-05-1974
			DE 2253927 A1	10-05-1973
			EG 11358 A	28-02-1977
			ES 408226 A1	01-02-1976
			ES 437311 A1	01-04-1977
			FR 2158464 A1	15-06-1973
			HU 169711 B	28-02-1977
			IE 37998 B1	07-12-1977
			IL 40521 A	25-06-1975
			JP 48056667 A	09-08-1973
			NL 7214807 A	07-05-1973
			PH 10303 A	10-11-1976
			SE 384856 B	24-05-1976
			SU 527135 A3	30-08-1976
			SU 577980 A3	25-10-1977
			US 3884919 A	20-05-1975
			US 4012513 A	15-03-1977
			ZA 7207007 A	27-06-1973
			AT 328433 B	25-03-1976
			AT 100374 A	15-06-1975
WO 0192224	A	06-12-2001	AU 5862801 A	11-12-2001
			BR 0111230 A	10-06-2003
			CA 2406979 A1	06-12-2001
			CN 1431999 T	23-07-2003

INTERNATIONAL SEARCH REPORT

International Application No
PCT/GB2004/003502

Patent document cited in search report	Publication date	Patent family member(s)	Publication date
WO 0192224	A	EP 1289952 A1	12-03-2003
		WO 0192224 A1	06-12-2001
		JP 2003535078 T	25-11-2003
		NO 20025696 A	27-11-2002
		NZ 522074 A	25-06-2004
		US 2003216356 A1	20-11-2003
		ZA 200208938 A	04-02-2004
WO 03101961	A1	11-12-2003	NONE
WO 2004007451	A1	22-01-2004	NONE
WO 03097598	A1	27-11-2003	NONE